EP1379658A2 - Peptides antimicrobiens et methodes d'utilisation - Google Patents

Peptides antimicrobiens et methodes d'utilisation

Info

Publication number
EP1379658A2
EP1379658A2 EP01970822A EP01970822A EP1379658A2 EP 1379658 A2 EP1379658 A2 EP 1379658A2 EP 01970822 A EP01970822 A EP 01970822A EP 01970822 A EP01970822 A EP 01970822A EP 1379658 A2 EP1379658 A2 EP 1379658A2
Authority
EP
European Patent Office
Prior art keywords
cys
lys
gly
pro
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01970822A
Other languages
German (de)
English (en)
Other versions
EP1379658B1 (fr
Inventor
Carl R. Simmons
Pedro A. Navarro Acevedo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pioneer Hi Bred International Inc
Original Assignee
Pioneer Hi Bred International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pioneer Hi Bred International Inc filed Critical Pioneer Hi Bred International Inc
Priority to EP08020600A priority Critical patent/EP2039769A3/fr
Publication of EP1379658A2 publication Critical patent/EP1379658A2/fr
Application granted granted Critical
Publication of EP1379658B1 publication Critical patent/EP1379658B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance

Definitions

  • the present invention relates generally to plant molecular biology. More specifically, it relates to nucleic acids and methods for modulating their expression in plants and to transforming genes into plants in order to enhance disease resistance.
  • Biotic causes include fungi, viruses, insects, bacteria, and nematodes. Of these, fungi are the most frequent causative agents of disease in plants.
  • Abiotic causes of disease in plants include extremes of temperature, water, oxygen, and soil pH, plus nutrient-element deficiencies and imbalances, excess heavy metals, and air pollution.
  • a host of cellular processes enables plants to defend themselves from disease caused by pathogenic agents. These processes apparently form an integrated set of resistance mechanisms that is activated by initial infection and then limits further spread ofthe invading pathogenic microorganism.
  • plants can activate an array of biochemical responses. Generally, the plant responds by inducing several local responses in the cells immediately surrounding the infection site. The most common resistance response observed in both nonhost and race-specific interactions is termed the "hypersensitive response" (HR). In the hypersensitive response, cells contacted by the pathogen, and often neighboring cells, rapidly collapse and dry in a necrotic fleck. Other responses include the deposition of callose, the physical thickening of cell walls by lignification, and the synthesis of various antibiotic small molecules and proteins. Genetic factors in both the host and the pathogen determine the specificity of these local responses, which can be very effective in limiting the spread of infection.
  • HR hypersensitive response
  • Phytopathogenic fungi play the dominant role. Phytopathogenic fungi cause devastating epidemics as well as significant annual crop yield losses. Pathogenic fungi attack all ofthe approximately 300,000 species of flowering plants. However, a single plant species can be host to only a few fungal species, and similarly, most fungi usually have a limited host range.
  • the antimicrobial peptide, snakin-1 has been isolated from potato tubers and found to be active against bacterial and fungal pathogens from potato and other plant species. Snakin-1 causes aggregation of both gram-positive and gram-negative bacteria.
  • the protein is homologous to amino acid sequences deduced from cDNAs that encode gibberellin-inducible rnRNAs. The protein also shares sequence motifs with kistrin and other hemotoxic snake venoms. Plant disease outbreaks have resulted in catastrophic crop failures that have triggered famines and caused major social change. Generally, the best strategy for plant disease control is to use resistant cultivars selected or developed by plant breeders for this purpose. However, the potential for serious crop disease epidemics persists today, as evidenced by outbreaks ofthe Victoria blight of oats and southern corn leaf blight. Accordingly, molecular methods are needed to supplement traditional breeding methods to protect plants from pathogen attack.
  • nucleic acids and proteins relating to disease resistance are generally herein referred to as KCP-like (lysine- and cysteine-rich peptides or nucleic acids encoding these peptides).
  • the present invention provides transgenic plants and seeds comprising the nucleic acids of the present invention, as well as transgenic plants and seeds modified to express a KCP-like polynucleotide. It is another object ofthe present invention to provide methods for modulating, in a transgenic plant, the expression ofthe nucleic acids of the present invention.
  • the present invention relates to an isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of: (a) a polynucleotide that encodes a polypeptide of SEQ ID NOS:37-72; (b) a polynucleotide comprising at least 20 contiguous bases of SEQ ID OS: 1-36; (c) a polynucleotide having at least 70% sequence identity to any of SEQ ID NOS: 1-36, wherein said polynucleotide encodes a polypeptide having KCP-like activity; (d) a polynucleotide at least 25 nucleotides in length that hybridizes to a polynucleotide having the sequence set forth in SEQ ID NOS: 1-36, wherein said polynucleotide encodes a polypeptide having KCP-like activity; (e) a polynucleotide comprising the sequence set forth in any of SEQ ID NOS: 1-
  • the present invention relates to vectors comprising the polynucleotides ofthe present invention. Also the present invention relates to recombinant expression cassettes, comprising a nucleic acid ofthe present invention operably linked to a promoter.
  • the present invention is directed to a host cell into which has been introduced the recombinant expression cassette.
  • the present invention relates to a transgenic plant or plant cell comprising a recombinant expression cassette with a promoter operably linked to any ofthe isolated nucleic acids ofthe present invention.
  • Plants containing the recombinant expression cassette ofthe present invention include but are not limited to maize, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice barley, or millet.
  • the present invention also provides transgenic seed from the transgenic plant.
  • the present invention relates to an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) an amino acid sequence comprising at least 25 contiguous amino acids ofthe sequence set forth in SEQ ID NOS:37-72; (b) an amino acid sequence having at least 75% sequence identity to the sequence set forth in SEQ ID NOS:37-72, wherein said polypeptide retains KCP-like activity; and, (c) an amino acid sequence comprising the sequences set forth in SEQ ID NOS:37-72.
  • the present invention relates to a method of modulating the level of protein in a plant by introducing into a plant cell a recombinant expression cassette comprising a polynucleotide ofthe present invention operably linked to a promoter, culturing the plant cell under plant growing conditions to produce a regenerated plant, and inducing expression ofthe polynucleotide for a time sufficient to modulate the protein ofthe present invention in the plant.
  • Plants ofthe present invention include but are not limited to maize, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice, barley, or millet.
  • the level of protein in the plant can either be increased or decreased.
  • the present invention is directed to a method for identifying KCP-like proteins, said method comprising: (a) searching at least one protein database with a pattern selected from the group consisting of: i) a pattern representing a compound having the formula (SEQ ID NO:97) C-X(2)-C-C-X(2)- [CS]-X(1,2)-C-V-P-[PSATK]-[GR]-X(2)-[GAQR], wherein: C is cysteine; X(2) is any two amino acids selected independently from one another; [CS] is one amino acid selected from the group consisting of cysteine and serine; X(l,2) is X(l) or X(2) wherein X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; V is valine; P is proline; [PSATK] is one amino acid selected from the group consisting of proline, serine, alanine, threonine, and lysine; [GR]
  • searching is performed utilizing PHI-BLAST or PHI-PSI-BLAST under parameters comprising a default Expectation value (E) of 10, a gap opening cost with a default value of 11 , and a gap extension cost with a default value of 1.
  • E Expectation value
  • the PHI-BLAST or PHI-PSI-BLAST is further used with BLOSUM62 substitution matrix.
  • Novel nucleic acid molecules and polypeptide sequences from maize, rice, wheat, and soybean are provided. These polypeptides are related to the potato snakin antimicrobial protein and GASA4 or GASA5 or GAST1 homologs in plants, and are referred to as KCP-like (lysine- and cysteine-rich peptides or nucleic acids encoding these peptides).
  • KCP-like proteins ofthe invention are generally lysine- and cysteine-rich; and the last three amino acids, which are universally conserved in the proteins ofthe invention, are K, C, and P, in that order.
  • the KCP-like polypeptides ofthe invention are natural plant protection proteins.
  • the KCP-like polypeptides ofthe invention are "antimicrobial,” by which is intended antibacterial, antiviral, and antifungal. Additionally, the polypeptides ofthe invention may enhance resistance to insects and nematodes. Consequently, the sequences ofthe invention are "anti-pathogenic: and therefore find use in the prevention and control of disease in plants.
  • the invention provides ectopic constitutive or inducible expression ofthe nucleotide sequences to enhance disease resistance in plants. In this manner, expression ofthe protein can be controlled such that the protein is expressed in the tissue or developmental stages to encounter the pathogen where it is most likely to strike.
  • the proteins also find use in controlling plant pathogens such as bacteria, fungi, insects, nematodes, and the like.
  • the KCP-like polypeptides ofthe invention can also be used for any application including coating surfaces to target microbes.
  • the target microbes include human pathogens or microorganisms.
  • Surfaces that might be coated with the KCP-like polypeptides ofthe invention include carpets and sterile medical facilities.
  • Polymer bound polypeptides ofthe invention may be used to coat surfaces. Methods for incorporating compositions with anti-microbial properties into polymers are known in the art. See U.S. Patent No. 5,847,047, herein incorporated by reference.
  • compositions ofthe invention in the treatment and preservation of textiles.
  • Insect pests devalue and destroy textiles and fabrics including, but not limited to, carpets, draperies, clothing, blankets, and bandages.
  • the compositions ofthe invention may be applied to finished textile products or may be expressed in plants yielding fibers that are incorporated into fabrics.
  • Insect pests that attack textiles include, but are not limited to, webbing clothes moths and carpet beetles.
  • nucleotide sequences including nine maize sequences, nine wheat sequences, two rice sequences, and twenty-one soybean sequences. Also provided are the polypeptides encoded by these nucleotide sequences. Nine sequences from Zea mays are provided (designated "Zm").
  • Zm-KCPl is a 730 nucleotide (nt) sequence (set forth in SEQ ID NO:l) that includes a 31 nt polyA tail (nt 700-730) and 699 nt exclusive ofthe polyA tail.
  • Nucleotides 1 -96 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 97-441 and a 3 nontranslated region at nt 442-699.
  • the predicted polypeptide sequence encoded by SEQ ID NO: 1 is set forth in SEQ ID NO:37.
  • Zm-KCP2 is a 549 nucleotide sequence (set forth in SEQ ID NO:2).
  • Nucleotides 1-241 correspond to a 5 nontranslated leader, with the coding region (ATG — stop) at nt 242-529 and a 3 nontranslated region at nt 530-549.
  • the predicted polypeptide sequence encoded by SEQ ID NO:2 is set forth in SEQ ID NO:38.
  • Zm-KCP3 is a 691 nucleotide (nt) sequence (set forth in SEQ ID NO:3) including a 10 nt polyA tail (nt 682-691) and 681 nt exclusive ofthe polyA tail.
  • Nucleotides 1-156 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 157-504 and a 3 nontranslated region at nt 505-681.
  • the predicted polypeptide sequence encoded by SEQ ID NO:3 is set forth in SEQ ID NO:39.
  • Zm-KCP4 is a 831 nucleotide sequence (set forth in SEQ ID NO:4) that includes an 18 nt polyA tail (nt 814-831) and 813 nt exclusive ofthe polyA tail.
  • Nucleotides 1-143 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 144-446 and a 3' nontranslated region at nt 447-813.
  • Zm-KCP5 is a 621 nucleotide sequence (set forth in SEQ ID NO: 5) that includes a 27 nt polyA tail (nt 595-621) and 594 nt exclusive ofthe polyA tail. Nucleotides 1-136 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 137-523 and a 3 nontranslated region at nt 524-594.
  • the predicted polypeptide sequence encoded by SEQ ID NO:5 is set forth in SEQ ID NO:41.
  • Zm-KCP6 is a 648 nucleotide sequence (set forth in SEQ ID NO:6) that includes an 18 nt polyA tail (nt 631-648) and 630 nt exclusive ofthe polyA tail. Nucleotides 1-141 correspond to a 5 nontranslated leader, with the coding region
  • SEQ ID NO:6 The predicted polypeptide sequence encoded by SEQ ID NO:6 is set forth in SEQ ID NO:42.
  • Zm-KCP7 is an 806 nucleotide sequence (set forth in SEQ ID NO:7) that includes a 33 nt polyA tail (nt 774-806) and 773 nt exclusive ofthe polyA tail. Nucleotides 1-135 correspond to a 5 nontranslated leader, with the coding region
  • SEQ ID NO:7 The predicted polypeptide sequence encoded by SEQ ID NO:7 is set forth in SEQ ID NO:43.
  • Zm-KCP8 is a 720 nucleotide sequence (set forth in SEQ ID NO:8) includes a 21 nt polyA tail (nt 700-720) and 699 nt exclusive ofthe polyA tail. Nucleotides 1- 118 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 119-403 and a 3 nontranslated region at nt 404-699.
  • the predicted polypeptide sequence encoded by SEQ ID NO:8 is set forth in SEQ ID NO:44.
  • Zm-KCP9 is a 754 nucleotide (nt) sequence (set forth in SEQ ID NO:9). Nucleotides 1-101 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 102-539 and a 3 nontranslated region at nt 540-754.
  • the predicted polypeptide sequence encoded by SEQ ID NO:9 is set forth in SEQ ID NO:45.
  • Ta-KCPl is a 594 nucleotide (nt) sequence (set forth in SEQ ID NO JO) that includes a 34 nt polyA tail (nt 561-594) and 560 nt exclusive ofthe polyA tail. Nucleotides 1-110 correspond to a 5 nontranslated leader, with the coding region
  • SEQ ID NO: 10 The predicted polypeptide sequence encoded by SEQ ID NO: 10 is set forth in SEQ ID NO:46.
  • Ta-KCP2 is a 677 nucleotide sequence (set forth in SEQ ID NO:l 1) including an 18 nt polyA tail (nt 660-677) and 659 nt exclusive ofthe polyA tail. Nucleotides 1-79 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 80-364 and a 3 nontranslated region at nt 365-659.
  • the predicted polypeptide sequence encoded by SEQ ID NO: 11 is set forth in SEQ ID NO:47.
  • Ta-KCP3 is a 639 nucleotide sequence (set forth in SEQ ID NO: 12) including a 27 nt polyA tail (nt 613-639) and 612 nt exclusive ofthe polyA tail.
  • Nucleotides 1- 80 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 81-377 and a 3 ' nontranslated region at nt 378-612.
  • the predicted polypeptide sequence encoded by SEQ ID NO:12 is set forth in SEQ ID NO:48.
  • Ta-KCP4 is a 506 nucleotide sequence (set forth in SEQ ID NO: 13). Nucleotide 1 corresponds to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 2-325 and a 3 nontranslated region at nt 326-506. The predicted polypeptide sequence encoded by SEQ ID NO: 13 is set forth in SEQ ID NO:49. Ta-KCP5 is a 506 nucleotide sequence (set forth in SEQ ID NO: 14).
  • Nucleotides 1-78 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 79-375 and a 3 nontranslated region at nt 376-506.
  • the predicted polypeptide sequence encoded by SEQ ID NO: 14 is set forth in SEQ ID NO:50.
  • Ta-KCP6 is a 769 nucleotide sequence (set forth in SEQ ID NO: 15) that includes a 20 nt polyA tail (nt 750-769) and 749 nt exclusive ofthe polyA tail.
  • Nucleotides 1-55 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 56-400 and a 3 nontranslated region at nt 401-749.
  • Ta-KCP7 is a 692 nucleotide sequence (set forth in SEQ ID NO: 16) that includes a 7 nt polyA tail (nt 686-692) and 685 nt exclusive ofthe polyA tail.
  • Nucleotides 1-136 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 137-448 and a 3 nontranslated region at nt 449-685.
  • the predicted polypeptide sequence encoded by SEQ ID NO: 16 is set forth in SEQ ID NO:52.
  • Two Ory ⁇ a sativa sequences are provided (designated "Os").
  • Os-KCP3 is a 685 nucleotide sequence (set forth in SEQ ID NO: 17).
  • Nucleotides 1-87 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 88-405, a 3 nontranslated region at nt 406-666, and a 19 nt polyA tail.
  • the predicted polypeptide sequence encoded by SEQ ID NO: 17 is set forth in SEQ ID NO:53.
  • Os-KCP4 is a 660 nucleotide sequence (set forth in SEQ ID NO: 18) that includes a 4 nt polyA tail (nt 657-660) and 656 nt exclusive ofthe polyA tail.
  • Nucleotides 1-75 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 76-330 and a 3 nontranslated region at nt 331 -656.
  • the predicted polypeptide sequence encoded by SEQ ID NO: 18 is set forth in SEQ ID NO:54.
  • Gm-KCPl is a 677 nucleotide (nt) sequence (set forth in SEQ ID NO: 19) that includes a 30 nt polyA tail (nt 648-677) and 647 nt exclusive ofthe polyA tail. Nucleotides 1-144 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 145-411 and a 3 nontranslated region at nt 412-647.
  • the predicted polypeptide sequence encoded by SEQ ID NO: 19 is set forth in SEQ ID NO:55.
  • Gm-KCP2 is a 756 nucleotide sequence (set forth in SEQ ID NO:20) that includes a 42 nt polyA tail (nt 715 -756) and 714 nt exclusive of the poly tail .
  • Nucleotides 1-146 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 147-413 and a 3 nontranslated region at nt 414-714.
  • the predicted polypeptide sequence encoded by SEQ ID NO:20 is set forth in SEQ ID NO:56.
  • Gm-KCP3 is a 579 nucleotide sequence (set forth in SEQ ID NO:21) that includes a 24 nt polyA tail (nt 556-579) and 555 nt exclusive ofthe polyA tail. Nucleotides 1-82 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 83-349 and a 3 nontranslated region at nt 350-555.
  • the predicted polypeptide sequence encoded by SEQ ID NO:21 is set forth in SEQ ID NO:57.
  • Gm-KCP4 is a 509 nucleotide sequence (set forth in SEQ ID NO:22) that includes a 19 nt polyA tail (nt 491-509) and 490 nt exclusive ofthe polyA tail. Nucleotides 1-51 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 52-324 and a 3 nontranslated region at nt 325-490.
  • the predicted polypeptide sequence encoded by SEQ ID NO:22 is set forth in SEQ ID NO: 58.
  • Gm-KCP5 is a 439 nucleotide sequence (set forth in SEQ ID NO:23) that includes an 18 nt polyA tail (nt 422-439) and 421 nt exclusive ofthe polyA tail. Nucleotides 1-16 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 17-289 and a 3 ' nontranslated region at nt 290-421.
  • the predicted polypeptide sequence encoded by SEQ ID NO:23 is set forth in SEQ ID NO:59.
  • Gm-KCP6 is a 783 nucleotide sequence (set forth in SEQ ID NO:24) that includes a 19 nt polyA tail (nt 765-783) and 764 nt exclusive ofthe polyA tail.
  • Nucleotides 1-54 correspond to a 5 nontranslated leader, with the coding region
  • the predicted polypeptide sequence encoded by SEQ ID NO:24 is set forth in SEQ ID NO:60.
  • Gm-KCP7 is a 607 nucleotide sequence (set forth in SEQ ID NO:25) that includes a 21 nt polyA tail (nt 587-607) and 586 nt exclusive ofthe polyA tail.
  • Nucleotides 1-38 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 39-386 and a 3 ' nontranslated region at nt 387-586.
  • the predicted polypeptide sequence encoded by SEQ ID NO:25 is set forth in SEQ ID NO:61.
  • Gm-KCP8 is a 788 nucleotide sequence (set forth in SEQ ID NO:26) that includes a 19 nt polyA tail (nt 770-788) and 769 nt exclusive ofthe polyA tail. Nucleotides 1-159 correspond to a 5 nontranslated leader, with the coding region (ATG- stop) at nt 160-513 and a 3 nontranslated region at nt 514-769.
  • the predicted polypeptide sequence encoded by SEQ ID NO:26 is set forth in SEQ ID NO:62.
  • Gm-KCP9 is a 996 nucleotide sequence (set forth in SEQ ID NO:27) that includes a 62 nt polyA tail (nt 935-996) and 934 nt exclusive ofthe polyA tail. Nucleotides 1-313 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 314-673 and a 3 nontranslated region at nt 674-934.
  • the predicted polypeptide sequence encoded by SEQ ID NO:27 is set forth in SEQ ID NO:63.
  • Gm-KCPIO is a 615 nucleotide sequence (set forth in SEQ ID NO:28) that includes a 22 nt polyA tail (nt 594-615) and 593 nt exclusive ofthe polyA tail. Nucleotides 1-63 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 64-363 and a 3 nontranslated region at nt 364-593.
  • the predicted polypeptide sequence encoded by SEQ ID NO:28 is set forth in SEQ ID NO:64.
  • Gm-KCPl 1 is a 628 nucleotide sequence (set forth in SEQ ID NO:29) that includes a 21 nt polyA tail (nt 608-628) and 607 nt exclusive ofthe polyA tail. Nucleotides 1-48 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 49-396 and a 3 nontranslated region nt 397-607.
  • the predicted polypeptide sequence encoded by SEQ ID NO:29 is set forth in SEQ ID NO:65.
  • Gm-KCPl 4 is a 1066 nucleotide sequence (set forth in SEQ ID NO:30) that includes a 17 nt polyA tail (nt 1050-1066) and 1049 nt exclusive ofthe polyA tail. Nucleotides 1-188 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 189-764 and a 3 ' nontranslated region at nt 765-1049.
  • the predicted polypeptide sequence encoded by SEQ ID NO:30 is set forth in SEQ ID NO:66.
  • Gm-KCP15 is a 697 nucleotide sequence (set forth in SEQ ID NO:31) that includes a 40 nt polyA tail (nt 658-697) and 657 nt exclusive ofthe polyA tail. Nucleotides 1-109 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 110-433 and a 3 ' nontranslated region at nt 434-657.
  • the predicted polypeptide sequence encoded by SEQ ID NO:31 is set forth in SEQ ID NO: 67.
  • Gm-KCP16 is a 692 nucleotide sequence (set forth in SEQ ID NO:32) that includes a 17 nt polyA tail (nt 676-692) and 675 nt exclusive ofthe polyA tail. Nucleotides 1-113 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 114-437 and a 3 nontranslated region at nt 438-675.
  • the predicted polypeptide sequence encoded by SEQ ID NO:32 is set forth in SEQ ID NO:68.
  • Gm-KCP17 is a 702 nucleotide sequence (set forth in SEQ ID NO:33) that includes a 22 nt polyA tail (nt 681 -702) and 680 nt exclusive of the polyA tail. Nucleotides 1-86 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 87-419 and a 3 nontranslated region at nt 420-680.
  • the predicted polypeptide sequence encoded by SEQ ID NO:33 is set forth in SEQ ID NO: 69.
  • Gm-KCPl 8 is a 783 nucleotide sequence (set forth in SEQ ID NO:34) that includes a 53 nt polyA tail (nt 731-783) and 730 nt exclusive ofthe polyA tail. Nucleotides 1-120 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 121-441 and a 3 nontranslated region at nt 442-730.
  • the predicted polypeptide sequence encoded by SEQ ID NO:34 is set forth in SEQ ID NO:70.
  • Gm-KCPl 9 is a 742 nucleotide sequence (set forth in SEQ ID NO:35) including a 47 nt polyA tail (nt 696-742) and 695 nt exclusive ofthe polyA tail.
  • Nucleotides 1-206 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 207-578 and a 3 nontranslated region at nt 579-695.
  • the predicted polypeptide sequence encoded by SEQ ID NO:35 is set forth in SEQ ID NO:71.
  • Gm-KCP20 is a 652 nucleotide sequence (set forth in SEQ ID NO:36) that includes a 32 nt polyA tail (nt 621-652) and 620 nt exclusive ofthe polyA tail. Nucleotides 1-93 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 94-387 and a 3 nontranslated region at nt 388-620.
  • the predicted polypeptide sequence encoded by SEQ ID NO:36 is set forth in SEQ ID NO: 72.
  • the KCP-like family of sequences appear to be conserved among dicot and monocot plants. There is nearly as great diversity of genes within species as between species. There are multiple genes for the sequences within a single plant species.
  • the KCP-like proteins are high in lysine, with an average lysine content of 10.8%.
  • the few proteins with low lysine content all had very high arginine content, arginine being another positively charged amino acid (and thus a conservative amino acid change).
  • All the proteins are basic with an average pi of 8.55, indicating that the proteins are cationic.
  • the proteins are small cysteine-rich, lysine-rich and cationic, all characteristics of many known antimicrobial proteins.
  • the KCP-like proteins ofthe invention can be used in combination with other antimicrobial proteins, such as defensin, thionin, chitinases, glucanases, and the like. Further, the activity ofthe polypeptides may be synergistic when used with such other antimicrobial proteins.
  • the present invention provides, among other things, compositions and methods for modulating ⁇ i.e., increasing or decreasing) the level of polynucleotides and polypeptides ofthe present invention in plants or any other host cell.
  • the polynucleotides and polypeptides ofthe present invention can be expressed temporally or spatially, e.g., at developmental stages, in tissues, and or in quantities, which are uncharacteristic of non-recombinantly engineered plants.
  • the present invention also provides isolated nucleic acid comprising polynucleotides of sufficient length and complementarity to a gene ofthe present mvention to use as probes or amplification primers in the detection, quantitation, or isolation of gene transcripts.
  • isolated nucleic acids ofthe present invention can be used as probes in detecting deficiencies in the level of mRNA in screenings for desired transgenic plants, for detecting mutations in the gene ⁇ e.g., substitutions, deletions, or additions), for monitoring upregulation of expression or changes in enzyme activity in compound screening assays, for detection of any number of allelic variants (polymorphisms), orthologs, or paralogs ofthe gene, or for site-directed mutagenesis in eukaryotic cells (see, e.g., U.S. patent No. 5,565,350).
  • the isolated nucleic acids ofthe present invention can also be used for recombinant expression of their encoded polypeptides, or for use as immunogens in the preparation and/or screening of antibodies.
  • the isolated nucleic acids ofthe present invention can also be employed for use in sense or antisense suppression of one or more genes of the present invention in a host cell, tissue, or plant. Attachment of chemical agents, which bind, intercalate, cleave and/or crosslink to the isolated nucleic acids ofthe present invention can also be used to modulate transcription or translation.
  • the present invention also provides isolated proteins comprising a polypeptide ofthe present invention ⁇ e.g., preproenzyme, proenzyme, or enzymes).
  • the isolated nucleic acids and proteins ofthe present invention can be used over a broad range of plant types, particularly monocots such as the species ofthe family Gramineae, including species ofthe genera. Sorghum ⁇ e.g. S. bicolor), Oryz ⁇ , Aven ⁇ , Hordeum, Sec ⁇ le, Triticum and Ze ⁇ mays, and dicots such as Glycine.
  • the isolated nucleic acid and proteins ofthe present invention can also be used in species from the genera: Cucurbita, Rosa, Vitis, Juglans, Fragaria, Lotus, Medicago, Onobrychis, Trifolium, Trigonella, Vigna, Citrus, Linum, Geranium, Manihot, Daucus, Arabidopsis, Brassica, Raphanus, Sinapis, Atropa, Capsicum, Datura, Hyoscyamus, Ly coper sicon, Nicotiana, Solanum, Petunia, Digitalis, Majorana, Ciahorium, Helianthus, Lactuca, Bromus, Asparagus, Antirrhinum, Heterocallis, Nemesis, Pelargonium, Panieum, Pennisetum, Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Pisum, Phaseolus, Lolium, andAllium.
  • plant species of interest include, but are not limited to, Brassica sp. (e.g., B. napus, B. rapa, B.junced), particularly those Brassica species useful as sources of seed oil, alfalfa ⁇ Medicago sativa), rice ⁇ Oryza sativa), rye ⁇ Secale cereale), sorghum ⁇ Sorghum vulgare), millet (e.g., pearl millet ⁇ Pennisetum glaucum), proso millet ⁇ Panieum miliaceum), foxtail millet ⁇ Setaria italica), finger millet ⁇ Eleusine coracan ⁇ j), sunflower ⁇ Helianthus annuus), safflower ⁇ Carthamus tinctorius), wheat ⁇ Triticum aestivum), soybean ⁇ Glycine max), tobacco ⁇ Nicotiana tabacum), potato ⁇ Solanum tuber osum), peanuts ⁇ Arachis hypo
  • Vegetables include tomatoes ⁇ Lycopersicon esculentum), lettuce (e.g., Lactuca sativa), green beans ⁇ Phaseolus vulgaris), lima beans ⁇ Phaseolus limensis), peas ⁇ Lathyrus spp.), and members ofthe genus Cucumis such as cucumber (C. sativus), cantaloupe (C. cantalupensis), and musk melon (C. melo).
  • lettuce e.g., Lactuca sativa
  • green beans ⁇ Phaseolus vulgaris
  • lima beans ⁇ Phaseolus limensis lima beans ⁇ Phaseolus limensis
  • members ofthe genus Cucumis such as cucumber (C. sativus), cantaloupe (C. cantalupensis), and musk melon (C. melo).
  • Ornamentals include azalea ⁇ Rhododendron spp.), hydrangea ⁇ Macrophylla hydrangea), hibiscus ⁇ Hibiscus rosasanensis), roses ⁇ Rosa spp.), tulips ⁇ Tulipa spp.), daffodils ⁇ Narcissus spp.), petunias ⁇ Petunia hybrid ⁇ ), carnation ⁇ Dianthus caryophyllus), poinsettia ⁇ Euphorbia pulcherrima), and chrysanthemum.
  • Conifers that may be employed in practicing the present invention include, for example, pines such as loblolly pine ⁇ Pinus taeda), slash pine ⁇ Pinus elliotii), ponderosa pine ⁇ Pinus ponderosa), lodgepole pine ⁇ Pinus contorta), and Monterey pine ⁇ Pinus radiata); Douglas-fir ⁇ Pseudotsuga menziesii); Western hemlock ⁇ Tsuga canadensis); Sitka spruce ⁇ Picea glauca); redwood ⁇ Sequoia sempervirens); true firs such as silver fir ⁇ Abies amabilis) and balsam fir ⁇ Abies balsamea); and cedars such as Western red cedar ⁇ Thuja plicata) and Alaska yellow-cedar ⁇ Chamaecyparis nootkatensis).
  • pines such as loblolly pine ⁇ Pin
  • plants ofthe present invention are crop plants (for example, corn, alfalfa, sunflower, Brassica, soybean, cotton, safflower, peanut, sorghum, wheat, millet, tobacco, etc.), more preferably corn and soybean plants, yet more preferably corn plants.
  • crop plants for example, corn, alfalfa, sunflower, Brassica, soybean, cotton, safflower, peanut, sorghum, wheat, millet, tobacco, etc.
  • plants of interest include grain plants that provide seeds of interest, oil- seed plants, and leguminous plants.
  • Seeds of interest include grain seeds, such as corn, wheat, barley, rice, sorghum, rye, etc.
  • Oil-seed plants include cotton, soybean, safflower, sunflower, Brassica, maize, alfalfa, palm, coconut, etc.
  • Leguminous plants include beans and peas. Beans include guar, locust bean, fenugreek, soybean, garden beans, cowpea, mungbean, lima bean, fava bean, lentils, chickpea, etc.
  • the invention is drawn to compositions and methods for inducing resistance in a plant to plant pests.
  • compositions and methods are also useful in protecting plants against fungal pathogens, viruses, nematodes, insects and the like.
  • disease resistance is intended that the plants avoid the disease symptoms that are the outcome of plant-pathogen interactions. That is, pathogens are prevented from causing plant diseases and the associated disease symptoms, or alternatively, the disease symptoms caused by the pathogen is minimized or lessened.
  • antipathogenic compositions is intended that the compositions ofthe invention have antipathogenic activity and thus are capable of suppressing, controlling, and/or killing the invading pathogenic organism.
  • An antipathogenic composition ofthe invention will reduce the disease symptoms resulting from pathogen challenge by at least about 5% to about 50%, at least about 10% to about 60%), at least about 30% to about 70%, at least about 40% to about 80%, or at least about 50% to about 90% or greater.
  • the methods ofthe invention can be utilized to protect plants from disease, particularly those diseases that are caused by plant pathogens.
  • Assays that measure antipathogenic activity are commonly known in the art, as are methods to quantitate disease resistance in plants following pathogen infection. See, for example, U.S. Patent No. 5,614,395, herein incorporated by reference. Such techniques include, measuring over time, the average lesion diameter, the pathogen biomass, and the overall percentage of decayed plant tissues. For example, a plant either expressing an antipathogenic polypeptide or having an antipathogenic composition applied to its surface shows a decrease in tissue necrosis ⁇ i.e., lesion diameter) or a decrease in plant death following pathogen challenge when compared to a control plant that was not exposed to the antipathogenic composition. Alternatively, antipathogenic activity can be measured by a decrease in pathogen biomass.
  • a plant expressing an antipathogenic polypeptide or exposed to an antipathogenic composition is challenged with a pathogen of interest.
  • tissue samples from the pathogen-inoculated tissues are obtained and RNA is extracted.
  • the percent of a specific pathogen RNA transcript relative to the level of a plant specific transcript allows the level of pathogen biomass to be determined. See, for example, Thomma et /. ⁇ 1998) Plant Biology 95:15107-15111, herein incorporated by reference.
  • in vitro antipathogenic assays include, for example, the addition of varying concentrations ofthe antipathogenic composition to paper disks and placing the disks on agar containing a suspension ofthe pathogen of interest. Following incubation, clear inhibition zones develop around the discs that contain an effective concentration ofthe antipathogenic polypeptide (Liu et al. (1994) Plant Biology 91 : 1888-1892, herein incorporated by reference). Additionally, microspectrophotometrical analysis can be used to measure the in vitro antipathogenic properties of a composition (Hu et al. (1997) Plant Mol. Biol. 34:949-959, and Cammue et al. (1992) J. Biol. Chem. 267: 2228-2233, both of which are herein incorporated by reference).
  • Pathogens ofthe invention include, but are not limited to, viruses or viroids, bacteria, insects, nematodes, fungi, and the like.
  • Viruses include any plant virus, for example, tobacco or cucumber mosaic virus, ringspot virus, necrosis virus, maize dwarf mosaic virus, etc.
  • Specific fungal and viral pathogens for the major crops include: Soybeans: Phytophthora megasperma fsp. glycinea, Macrophomina phaseolina, Rhizoctonia solani, Sclerotinia sclerotiorum, Fusarium oxysporum, Diaporthe phaseolorum var. sojae (Phomopsis sojae), Diaporthe phaseolorum var.
  • glycinea Xanthomonas campestris p.v.phaseoli, Microsphaera diffusa, Fusarium semitectum, Phialophora gregata, Soybean mosaic virus, Glomerella glycines, Tobacco Ring spot virus, Tobacco Streak virus, Phakopsora pachyrhizi, Pythium aphanidermatum, Pythium ultimum, Pythium debaryanum, Tomato spotted wilt virus, Heterodera glycines Fusarium solani; Canola: Albugo Candida, Alternaria brassicae, Leptosphaeria maculans, Rhizoctonia solani, Sclerotinia sclerotiorum, Mycosphaerella brassiccola, Pythium ultimum, Peronospora parasitica, Fusarium roseum, Alternaria alternata; Alfalfa: Clavibater michiganese subsp.
  • Pseudomonas syringae p.v. syringae Alternaria alternata, Cladosporium herbarum, Fusarium graminearum, Fusarium avenaceum, Fusarium culmorum, Ustilago tritici, Ascochyta tritici, Cephalosporium gramineum, Collotetrichum graminicola, Erysiphe graminis f.sp. tritici, Puccinia graminis f.sp. tritici, Puccinia recondita f.sp.
  • Peronosclerosporaphilippinensis Peronosclerospora maydis, Peronosclerospora sacchari, Sphacelotheca reiliana, Physopella zeae, Cephalosporium maydis, Cephalosporium acremonium, Maize Chlorotic Mottle Virus, High Plains Virus, Maize Mosaic Virus, Maize Rayado Fino Virus, Maize Streak Virus, Maize Stripe Virus, Maize Rough Dwarf Virus; Sorghum: Exserohilum turcicum, Colletotrichum graminicola (Glomerella graminicola), Cercospora sorghi, Gloeocercospora sorghi, Ascochyta sorghina, Pseudomonas syringae p.v.
  • Nematodes include parasitic nematodes such as root-knot, cyst, and lesion nematodes, including Heterodera and Globodera spp; particularly Globodera rostochiensis and globodera pailida (potato cyst nematodes); Heterodera glycines (soybean cyst nematode); Heterodera schachtii (beet cyst nematode); and Heterodera avenae (cereal cyst nematode).
  • Insect pests include insects selected from the orders Coleoptera, Diptera, Hymenoptera, Lepidoptera, Mallophaga, Homoptera, Hemiptera, Orthoptera, Thysanoptera, Dermaptera, Isoptera, Anoplura, Siphonaptera, Trichoptera, etc., particularly Coleoptera and Lepidoptera.
  • Insect pests ofthe invention for the major crops include: Maize: Ostrinia nubilalis, European corn borer; Agrotis ipsilon, black cutworm; Helicoverpa zea, corn earworm; Spodoptera frugiperda, fall armyworm; Diatraea grandiosella, southwestern corn borer; Elasmopalpus lignosellus, lesser cornstalk borer; Diatraea saccharalis, surgarcane borer; Diabrotica virgifera, western corn rootworm; Diabrotica longicornis barberi, northern corn rootworm; Diabrotica undecimpunctata howardi, southern corn rootworm; Melanotus spp., wire worms;
  • nucleic acids are written left to right in 5 to 3 orientation, and amino acid sequences are written left to right in amino to carboxy orientation, respectively.
  • Numeric ranges are inclusive ofthe numbers defining the range and include each integer within the defined range.
  • Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
  • Nucleotides likewise, may be referred to by their commonly accepted single-letter codes. The terms defined below are more fully defined by reference to the specification as a whole.
  • amplified is meant the construction of multiple copies of a nucleic acid sequence or multiple copies complementary to the nucleic acid sequence using at least one ofthe nucleic acid sequences as a template.
  • Amplification systems include the polymerase chain reaction (PCR) system, ligase chain reaction (LCR) system, nucleic acid sequence based amplification (NASBA, Cangene, Mississauga, Ontario), Q-Beta Replicase systems, transcription-based amplification system (TAS), and strand displacement amplification (SDA). See, e.g., Diagnostic Molecular Microbiology: Principles and Applications, DH Persing et al, Ed., American Society for
  • the product of amplification is termed an amplicon.
  • antisense orientation includes reference to a duplex polynucleotide sequence which is operably linked to a promoter in an orientation where the antisense strand is transcribed.
  • the antisense strand is sufficiently complementary to an endogenous transcription product such that translation ofthe endogenous transcription product is often inhibited.
  • nucleic acid comprises the information for translation into the specified protein.
  • a nucleic acid encoding a protein may comprise non-translated sequences ⁇ e.g., introns) within translated regions ofthe nucleic acid, or may lack such intervening non-translated sequences ⁇ e.g., as in cDNA).
  • the information by which a protein is encoded is specified by the use of codons.
  • the amino acid sequence is encoded by the nucleic acid using the "universal" genetic code.
  • variants ofthe universal code such as are present in some plant, animal, and fungal mitochondria, the bacterium Mycoplasma capricolum, or the ciliate Macronucleus, may be used when the nucleic acid is expressed therein.
  • nucleic acid sequences ofthe present invention may be expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of monocotyledons or dicotyledons, as these preferences have been shown to differ (Murray et al. (1989) Nucl. Acids Res. 17: 477-498).
  • the maize preferred codon for a particular amino acid might be derived from known gene sequences from maize.
  • heterologous in reference to a nucleic acid means a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention.
  • a promoter operably linked to a heterologous structural gene is from a species different from that species from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form.
  • a heterologous protein may originate from a foreign species, or, if from the same species, is substantially modified from its original form by deliberate human intervention.
  • host cell is meant a cell which contains a vector and supports the replication and/or expression ofthe vector.
  • Host cells may be prokaryotic cells such as E. coli or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells.
  • host cells are monocotyledonous or dicotyledonous plant cells.
  • a particularly preferred monocotyledonous host cell is a maize host cell.
  • the term "introduced” in the context of inserting a nucleic acid into a cell means “transfection” or “transformation” or “transduction” and includes reference to the incorporation of a nucleic acid into a eukaryotic or prokaryotic cell where the nucleic acid may be inco ⁇ orated into the genome ofthe cell ⁇ e.g., chromosome, plasmid, plastid or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed ⁇ e.g., transfected mRNA).
  • marker includes reference to a locus on a chromosome that serves to identify a unique position on the chromosome.
  • a "polymorphic marker” includes reference to a marker which appears in multiple forms (alleles) such that different forms ofthe marker, when they are present in a homologous pair, allow one of skill in the art to follow the transmission of each ofthe chromosomes of that pair. Use of one or a plurality of markers may define a genotype.
  • nucleic acid includes reference to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited encompasses known analogues having the essential nature of natural nucleotides in that they hybridize to single-stranded nucleic acids in a manner similar to naturally occurring nucleotides ⁇ e.g., peptide nucleic acids).
  • nucleic acid library is meant a collection of isolated DNA or RNA molecules which comprise and substantially represent the entire transcribed fraction of a genome of a specified organism. Construction of exemplary nucleic acid libraries, such as genomic and cDNA libraries, is taught in standard molecular biology references such as: Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol. 152, Academic Press, Inc., San Diego, CA (Berger); Sambrook et al. (1989) Molecular Cloning - A Laboratory Manual, 2 n ed., Vol. 1-3; and Current Protocols in Molecular Biology, F.M. Ausubel et al, Eds., Current Protocols, a joint venture between Greene Publishing Associates, h e. and John Wiley & Sons, Inc. (1994).
  • polynucleotide includes reference to a deoxyribopolynucleotide, ribopolynucleotide, or analogs thereof that have the essential nature of a natural ribonucleotide in that they hybridize, under stringent hybridization conditions, to substantially the same nucleotide sequence as naturally occurring nucleotides and/or allow translation into the same amino acid(s) as the naturally occurring nucleotide(s).
  • a polynucleotide can be full-length or a subsequence of a native or heterologous structural or regulatory gene. Unless otherwise indicated, the term includes reference to the specified sequence as well as the complementary sequence thereof.
  • DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein.
  • DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art.
  • polynucleotide as it is employed herein embraces such chemically, enzymatically, or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including among other things simple and complex cells.
  • polypeptide polypeptide
  • peptide protein
  • proteins are used interchangeably herein to refer to a polymer of amino acid residues.
  • the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid.
  • the terms also apply to naturally occurring amino acid polymers.
  • the essential nature of such analogues of naturally occurring amino acids is that when incorporated into a protein, that protein is specifically reactive to antibodies elicited to a protein having the same amino acid sequence but consisting entirely of naturally occurring amino acids.
  • polypeptide “peptide,” and “protein” are also inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation. It will be appreciated, as is well known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination and they may be circular (with or without branching), generally as a result of post-translation events, including natural processing event and events brought about by human manipulation which do not occur naturally.
  • Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods as well. Further, this invention contemplates the use of both the methionine-containing and the methionine-less amino terminal variants ofthe protein ofthe invention.
  • the invention encompasses isolated or substantially purified nucleic acid or protein compositions.
  • An "isolated” or “purified” nucleic acid molecule or protein, or biologically active portion thereof, is substantially or essentially free from components that normally accompany or interact with the nucleic acid molecule or protein as found in its naturally occurring environment.
  • an isolated or purified nucleic acid molecule or protein is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
  • an "isolated" nucleic acid is free of sequences (preferably protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends ofthe nucleic acid) in the genomic DNA ofthe organism from which the nucleic acid is derived.
  • the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0J kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA ofthe cell from which the nucleic acid is derived.
  • a protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of contaminating protein.
  • culture medium represents less than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of chemical precursors or non-protein-of-interest chemicals.
  • operably linked includes reference to a functional linkage between a promoter and a second sequence wherein the promoter sequence initiates and mediates transcription ofthe DNA sequence corresponding to the second sequence.
  • operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.
  • promoter includes reference to a region of DNA upstream from the start of transcription and involved in recognition and binding of RNA polymerase and other proteins to initiate transcription.
  • a "plant promoter” is a promoter capable of initiating transcription in plant cells whether or not its origin is a plant cell. Exemplary plant promoters include but are not limited to those that are obtained from plants, plant viruses, and bacteria which comprise genes expressed in plant cells, such as Agrobacterium or Rhizobium. Examples of promoters under developmental control include promoters that preferentially initiate transcription in certain tissues, such as leaves, roots, or seeds.
  • tissue preferred Such promoters are referred to as "tissue preferred.”
  • a "cell-type-preferred” promoter preferentially drives expression in certain cell types in one or more organs, for example, vascular cells in roots or leaves.
  • An “inducible” or “repressible” promoter is a promoter which is under environmental control, or affected by environmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions or the presence of light.
  • Tissue-preferred, cell-type-preferred, and inducible promoters constitute the class of "non-constitutive" promoters.
  • a “constitutive” promoter is a promoter which is active under most environmental conditions.
  • recombinant includes reference to a cell or vector that has been modified by the introduction of a heterologous nucleic acid or that the cell is derived from a cell so modified.
  • recombinant cells express genes that are not found in identical form within the native (non-recombinant) form ofthe cell or express native genes that are otherwise abnormally expressed, under- expressed, or not expressed at all as a result of deliberate human intervention.
  • the term "recombinant” as used herein does not encompass the alteration ofthe cell or vector by naturally occurring events ⁇ e.g., spontaneous mutation and natural transformation, transduction, or transposition), such as those occurring without deliberate human intervention.
  • a "recombinant expression cassette” is a nucleic acid construct generated recombinantly or synthetically and having a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a host cell.
  • the recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment.
  • the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid to be transcribed and a promoter.
  • amino acid residue or “amino acid residue” or “amino acid” are used interchangeably herein to refer to an amino acid that is incorporated into a protein, polypeptide, or peptide (collectively, “protein”).
  • the amino acid may be a naturally occurring amino acid and, unless otherwise limited, may encompass non-natural analogs of natural amino acids that can function in a manner similar to that of naturally occurring amino acids.
  • sequences include a reference to hybridization, under stringent hybridization conditions, of a nucleic acid sequence to a specified nucleic acid target sequence to a detectably greater degree ⁇ e.g., at least 2-fold over background) than its hybridization to non-target nucleic acid sequences and to the substantial exclusion of non-target nucleic acids.
  • Selectively hybridizing sequences typically have about at least 80% sequence identity, preferably 90% sequence identity, and most preferably 100% sequence identity ⁇ i.e., complementarity) with each other.
  • nucleotide sequences ofthe invention can be used to isolate corresponding sequences from other organisms, particularly other plants. In this manner, methods such as PCR, hybridization, and the like can be used to identify such sequences based on their sequence homology to the sequences set forth herein.
  • sequences include sequences that are orthologs ofthe disclosed sequences.
  • orthologs is intended genes derived from a common ancestral gene and which are found in different species as a result of speciation. Genes found in different species are considered orthologs when their nucleotide sequences and/or their encoded protein sequences share substantial identity as defined elsewhere herein. Functions of orthologs are often highly conserved among species.
  • isolated sequences that encode a KCP-like polypeptide and which hybridize under stringent conditions to the sequences disclosed herein, or to fragments thereof, are encompassed by the present invention.
  • oligonucleotide primers can be designed for use in PCR reactions to amplify corresponding DNA sequences from cDNA or genomic DNA extracted from any organism of interest.
  • Methods for designing PCR primers and PCR cloning are generally known in the art and are disclosed in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). See also Innis et al, eds. (1990) PCR Protocols: A Guide to Methods and Applications (Academic Press, New York); Innis and Gelfand, eds.
  • PCR PCR Strategies
  • nested primers single specific primers
  • degenerate primers gene-specific primers
  • vector- specific primers partially-mismatched primers
  • hybridization techniques all or part of a known nucleotide sequence is used as a probe that selectively hybridizes to other corresponding nucleotide sequences present in a population of cloned genomic DNA fragments or cDNA fragments (i.e., genomic or cDNA libraries) from a chosen organism.
  • the hybridization probes may be genomic DNA fragments, cDNA fragments, RNA fragments, or other oligonucleotides, and may be labeled with a detectable group such as 32 P, or any other detectable marker.
  • probes for hybridization can be made by labeling synthetic oligonucleotides based on the KCP-like sequences ofthe invention.
  • probes for hybridization and for construction of cDNA and genomic libraries are generally known in the art and are disclosed in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).
  • the entire KCP-like sequences disclosed herein, or one or more portions thereof may be used as a probe capable of specifically hybridizing to corresponding KCP-like sequences and messenger RNAs.
  • probes include sequences that are unique among KCP-like sequences and are preferably at least about 10 nucleotides in length, and most preferably at least about 20 nucleotides in length.
  • Such probes may be used to amplify corresponding KCP-like sequences from a chosen plant or other organism by PCR. This technique may be used to isolate additional coding sequences from a desired plant or other organism or as a diagnostic assay to determine the presence of coding sequences in a plant or other organism.
  • Hybridization techniques include hybridization screening of plated DNA libraries (either plaques or colonies; see, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).
  • Hybridization of such sequences may be carried out under stringent conditions.
  • stringent conditions or “stringent hybridization conditions” is intended conditions under which a probe will hybridize to its target sequence to a detectably greater degree than to other sequences (e.g., at least 2-fold over background).
  • Stringent conditions are sequence-dependent and will be different in different circumstances.
  • target sequences that are 100% complementary to the probe can be identified (homologous probing).
  • stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing).
  • a probe is less than about 1000 nucleotides in length, preferably less than 500 nucleotides in length.
  • stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides).
  • Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
  • Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1%
  • Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to IX SSC at 55 to 60°C.
  • Exemplary high stringency conditions include hybridization in 50%> formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in OJX SSC at 60 to 65°C.
  • wash buffers may comprise about 0.1% to about 1% SDS. Duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours.
  • T m 81.5°C + 16.6 (log M) + 0.41 (%GC) - 0.61 (% form) - 500/L; where M is the molarity of monovalent cations, %>GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length ofthe hybrid in base pairs.
  • the T m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T m is reduced by about 1°C for each 1% of mismatching; thus, T m , hybridization, and/or wash conditions can be adjusted to hybridize to sequences ofthe desired identity. For example, if sequences with >90% identity are sought, the T m can be decreased 10°C. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence and its complement at a defined ionic strength and pH.
  • Plant cell as used herein includes without limitation seeds, suspension cultures, embryos, meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores.
  • the class of plants which can be used in the methods ofthe invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants.
  • Preferred plants include but are not limited to maize, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice, barley, and millet.
  • a particularly preferred plant is maize ⁇ Zea mays).
  • transgenic plant refers to a plant which comprises within its genome a heterologous polynucleotide.
  • the heterologous polynucleotide is stably integrated within the genome such that the polynucleotide is passed on to successive generations.
  • the heterologous polynucleotide may be integrated into the genome alone or as part of a recombinant expression cassette.
  • Transgenic is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acid.
  • the term “transgenic” includes those transgenics initially so altered as well as those created by sexual crosses or asexual propagation from the initial transgenic.
  • transgenic does not encompass the alteration ofthe genome (chromosomal or extra-chromosomal) by conventional plant breeding methods or by naturally occurring events such as random cross-fertilization, non-recombinant viral infection, non-recombinant bacterial transformation, non-recombinant transposition, or spontaneous mutation.
  • vector includes reference to a nucleic acid used in transfection of a host cell and into which can be inserted a polynucleotide. Vectors are often replicons. Expression vectors permit transcription of a nucleic acid inserted therein.
  • the following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) “reference sequence”, (b) “comparison window”, (c) “sequence identity”, (d) "percentage of sequence identity”, and (e) “substantial identity”.
  • reference sequence is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.
  • comparison window makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment ofthe two sequences.
  • the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer.
  • a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used with the ALIGN program when comparing amino acid sequences.
  • the BLAST programs of Altschul et al (1990) J. Mol. Biol. 215:403 are based on the algorithm of Karlin and Altschul (1990) supra.
  • Gapped BLAST in BLAST 2.0
  • PSI-BLAST in BLAST 2.0
  • the default parameters ofthe respective programs e.g., BLASTN for nucleotide sequences, BLASTX for proteins
  • Alignment may also be performed manually by inspection.
  • sequence identity/similarity values refer to the value obtained using GAP version 10 using the following parameters: % identity using GAP Weight of 50 and Length Weight of 3; % similarity using Gap Weight of 12 and Length Weight of 4, or any equivalent program.
  • equivalent program is intended any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by GAP Version 10.
  • GAP uses the algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:
  • GAP finds the alignment of two complete sequences that maximizes the number of matches and minimizes the number of gaps.
  • GAP considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. It allows for the provision of a gap creation penalty and a gap extension penalty in units of matched bases. GAP must make a profit of gap creation penalty number of matches for each gap it inserts. If a gap extension penalty greater than zero is chosen, GAP must, in addition, make a profit for each gap inserted ofthe length ofthe gap times the gap extension penalty. Default gap creation penalty values and gap extension penalty values in Version 10 ofthe Wisconsin Genetics Software Package for protein sequences are 8 and 2, respectively.
  • the default gap creation penalty is 50 while the default gap extension penalty is 3.
  • the gap creation and gap extension penalties can be expressed as an integer selected from the group of integers consisting of from 0 to 200. Thus, for example, the gap creation and gap extension penalties can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or greater.
  • GAP presents one member ofthe family of best alignments. There may be many members of this family, but no other member has a better quality. GAP displays four figures of merit for alignments: Quality, Ratio, Identity, and Similarity. The Quality is the metric maximized in order to align the sequences. Ratio is the quality divided by the number of bases in the shorter segment.
  • Percent Identity is the percent ofthe symbols that actually match.
  • Percent Similarity is the percent ofthe symbols that are similar. Symbols that are across from gaps are ignored. A similarity is scored when the scoring matrix value for a pair of symbols is greater than or equal to 0.50, the similarity threshold.
  • the scoring matrix used in Version 10 ofthe Wisconsin Genetics Software Package is BLOSUM62 (see Henikoff and Henikoff (1989) Proc. Natl Acad. Sci. USA SP: 10915).
  • sequence identity or “identity” in the context of two nucleic acid or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window.
  • percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties ofthe molecule.
  • sequences differ in conservative substitutions the percent sequence identity may be adjusted upwards to correct for the conservative nature ofthe substitution.
  • Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity”. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California).
  • percentage of sequence identity means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion ofthe polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.
  • polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70%) sequence identity, preferably at least 80%, more preferably at least 90%>, and most preferably at least 95%o, compared to a reference sequence using one ofthe alignment programs described using standard parameters.
  • sequence identity preferably at least 80%, more preferably at least 90%>, and most preferably at least 95%o, compared to a reference sequence using one ofthe alignment programs described using standard parameters.
  • Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%.
  • nucleotide sequences are substantially identical if two molecules hybridize to each other under stringent conditions.
  • stringent conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH.
  • T m thermal melting point
  • stringent conditions encompass temperatures in the range of about 1°C to about 20°C lower than the T m , depending upon the desired degree of stringency as otherwise qualified herein.
  • Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.
  • One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.
  • substantially identical in the context of a peptide indicates that a peptide comprises a sequence with at least 70% sequence identity to a reference sequence, preferably 80%, more preferably 85%>, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window.
  • optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 45:443-453.
  • An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide.
  • a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution.
  • Peptides that are "substantially similar” share sequences as noted above except that residue positions that are not identical may differ by conservative amino acid changes.
  • the present invention provides, among other things, isolated nucleic acids of RNA, DNA, and analogs and/or chimeras thereof, comprising a polynucleotide ofthe present invention.
  • a polynucleotide ofthe present invention is inclusive of: (a) a polynucleotide encoding a polypeptide of any of SEQ ID NOS:37-72, including exemplary polynucleotides of SEQ ID NOS: 1-36;
  • nucleic acid library using primer pairs which selectively hybridize under stringent conditions to loci within a polynucleotide selected from the group consisting of SEQ ID NOSJ-36;
  • a polynucleotide comprising at least 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or 70 contiguous nucleotides from a polynucleotide of (a), (b), (c), (d), or (e); and
  • an isolated polynucleotide made by the process of: 1) providing a full- length enriched nucleic acid library, 2) selectively hybridizing the polynucleotide to a polynucleotide of (a), (b), (c), (d), (e), (f), (g), or (h), thereby isolating the polynucleotide from the nucleic acid library.
  • the present invention provides, among other things, isolated nucleic acids of
  • RNA, DNA, and analogs and/or chimeras thereof, comprising a polynucleotide ofthe present invention comprising a polynucleotide ofthe present invention.
  • A. Polynucleotides Encoding a Polypeptide ofthe Present Invention provides isolated nucleic acids comprising a polynucleotide ofthe present invention, wherein the polynucleotide encodes a polypeptide ofthe present invention. Every nucleic acid sequence herein that encodes a polypeptide also, by reference to the genetic code, describes every possible silent variation ofthe nucleic acid.
  • each codon in a nucleic acid except AUG, which is ordinarily the only codon for methionine; and UGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule.
  • each silent variation of a nucleic acid which encodes a polypeptide ofthe present invention, is implicit in each described polypeptide sequence and is within the scope ofthe present invention. Accordingly, the present invention includes polynucleotides ofthe present invention and polynucleotides encoding a polypeptide ofthe present invention.
  • the present invention provides an isolated nucleic acid comprising a polynucleotide ofthe present invention, wherein the polynucleotides are amplified under nucleic acid amplification conditions from a plant nucleic acid library.
  • Nucleic acid amplification conditions for each ofthe variety of amplification methods are well known to those of ordinary skill in the art.
  • the plant nucleic acid library can be constructed from a monocot such as a cereal crop. Exemplary cereals include corn, sorghum, alfalfa, canola, wheat, or rice.
  • the plant nucleic acid library can also be constructed from a dicot such as soybean.
  • Zea mays lines B73, PHRE1, A632, BMS- P2#l 0, W23, and Mo 17 are known and publicly available. Other publicly known and available maize lines can be obtained from the Maize Genetics Cooperation (Urbana, IL). Wheat lines are available from the Wheat Genetics Resource Center (Manhattan, KS).
  • the nucleic acid library may be a cDNA library, a genomic library, or a library generally constructed from nuclear transcripts at any stage of intron processing.
  • cDNA libraries can be normalized to increase the representation of relatively rare cDNAs.
  • the cDNA library is constructed using an enriched full-length cDNA synthesis method. Examples of such methods include Oligo-Capping (Maruyama and Sugano (1994) Gene 138: 171-174), Biotinylated CAP Trapper (Carninci et al. ( 1996) Genomics 37: 327-336), and CAP Retention Procedure (Edery et al. (1995) Molecular and Cellular Biology 15: 3363- 3371).
  • Rapidly growing tissues or rapidly dividing cells are preferred for use as an mRNA source for construction of a cDNA library. Growth stages of corn is described in "How a Corn Plant Develops,” Special Report No. 48, Iowa State University of Science and Technology Cooperative Extension Service, Ames, Iowa, Reprinted February 1993.
  • a polynucleotide of this embodiment (or subsequences thereof) can be obtained, for example, by using amplification primers which are selectively hybridized and primer extended, under nucleic acid amplification conditions, to at least two sites within a polynucleotide ofthe present invention, or to two sites within the nucleic acid which flank and comprise a polynucleotide ofthe present invention, or to a site within a polynucleotide ofthe present invention and a site within the nucleic acid which comprises it.
  • Methods for obtaining 5 and/or 3 ends of a vector insert are well known in the art. See, e.g.
  • the primers are complementary to a subsequence ofthe target nucleic acid which they amplify but may have a sequence identity ranging from about 85% to 99% relative to the polynucleotide sequence which they are designed to anneal to.
  • the sites to which the primer pairs will selectively hybridize are chosen such that a single contiguous nucleic acid can be formed under the desired nucleic acid amplification conditions.
  • the primer length in nucleotides is selected from the group of integers consisting of from at least 15 to 50.
  • the primers can be at least 15, 18, 20, 25, 30, 40, or 50 nucleotides in length.
  • a lengthened primer sequence can be employed to increase specificity of binding ⁇ i.e., annealing) to a target sequence.
  • a non-annealing sequence at the 5 end of a primer (a "tail") can be added, for example, to introduce a cloning site at the terminal ends ofthe amplicon.
  • the amplification products can be translated using expression systems well known to those of skill in the art.
  • the resulting translation products can be confirmed as polypeptides ofthe present invention by, for example, assaying for the appropriate catalytic activity (e.g., specific activity and/or substrate specificity), or verifying the presence of one or more linear epitopes, which are specific to a polypeptide ofthe present invention.
  • Methods for protein synthesis from PCR derived templates are known in the art and available commercially. See, e.g., Amersham Life Sciences, Inc, Catalog '97, p.354.
  • polynucleotides that Selectively Hybridize to a Polynucleotide of (A) or (B) The present invention provides isolated nucleic acids comprising polynucleotides ofthe present invention, wherein the polynucleotides selectively hybridize, under selective hybridization conditions, to a polynucleotide of section (A) or (B) as discussed above.
  • the polynucleotides of this embodiment can be used for isolating, detecting, and/or quantifying nucleic acids comprising the polynucleotides of section (A) or (B).
  • polynucleotides ofthe present invention can be used to identify, isolate, or amplify partial or full-length clones in a deposited library.
  • the polynucleotides are genomic or cDNA sequences isolated or otherwise complementary to a cDNA from a dicot or monocot nucleic acid library.
  • Exemplary species of monocots and dicots include, but are not limited to: maize, canola, soybean, cotton, wheat, sorghum, sunflower, alfalfa, oats, sugar cane, millet, barley, and rice.
  • the cDNA library comprises at least 50% to 95%) full-length sequences (for example, at least 50%, 60%, 70%, 80%, 90%, or 95% full- length sequences).
  • the cDNA libraries can be normalized to increase the representation of rare sequences. See, e.g., U.S. Patent No. 5,482,845.
  • Low stringency hybridization conditions are typically, but not exclusively, employed with sequences having a reduced sequence identity relative to complementary sequences.
  • Moderate and high stringency conditions can optionally be employed for sequences of greater identity.
  • the present invention provides isolated nucleic acids comprising polynucleotides ofthe present invention, wherein the polynucleotides have a specified identity at the nucleotide level to a polynucleotide as disclosed above in sections (A), (B), or (C), above.
  • Identity can be calculated using, for example, the BLAST or GAP algorithms as described elsewhere herein.
  • the percentage of identity to a reference sequence is at least 60%> and, rounded upwards to the nearest integer, can be expressed as an integer selected from the group of integers consisting of from 60 to 99.
  • the percentage of identity to a reference sequence can be at least about 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
  • the present invention provides isolated nucleic acids comprising polynucleotides ofthe present invention, wherein the polynucleotides encode a protein having a subsequence of contiguous amino acids from a prototype polypeptide ofthe present invention such as are provided in section (A), above.
  • the subsequences of a nucleotide sequence may encode protein fragments that retain the biological activity ofthe native protein and hence KCP-like activity.
  • subsequences of a nucleotide sequence that are useful as hybridization probes generally do not encode fragment proteins retaining biological activity.
  • subsequences of a nucleotide sequence may range from at least about 20 nucleotides, about 50 nucleotides, about 100 nucleotides, and up to the full-length nucleotide sequence encoding the proteins ofthe invention.
  • the length of contiguous amino acids from the prototype polypeptide is selected from the group of integers consisting of from at least 10 to the number of amino acids within the prototype sequence.
  • the polynucleotide can encode a polypeptide having a biologically active subsequence having at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 contiguous amino acids from the prototype polypeptide.
  • the number of such subsequences encoded by a polynucleotide ofthe instant embodiment can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5.
  • the subsequences can be separated by any integer of nucleotides from 1 to the number of nucleotides in the sequence such as at least 5, 10, 15, 25, 50, 100, or 200 nucleotides.
  • a subsequence of a KCP-like nucleotide sequence may encode a biologically active portion of a KCP-like protein, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed below.
  • a biologically active portion of a KCP-like protein can be prepared by isolating a portion of one ofthe KCP-like nucleotide sequences ofthe invention, expressing the encoded portion ofthe KCP-like protein (e.g., by recombinant expression in vitro), and assessing the activity ofthe encoded portion ofthe KCP-like protein.
  • Nucleic acid molecules that are subsequences of a KCP-like nucleotide sequence comprise at least 16, 20, 50, 75, 100, 150, 200, 250, 300, 350, or 400 nucleotides, or up to the number of nucleotides present in a full-length KCP-like nucleotide sequence disclosed herein (for example, 730 nucleotides for SEQ ID NO: 1 , 549 nucleotides for SEQ ID
  • subsequences or fragments retaining biological activity a variety of methods are contemplated for measuring the activity of such subsequences or fragments, including both in vivo and in silico methods.
  • biological activity of a subsequence or fragment may be determined using any ofthe variety of biological assays described elsewhere herein.
  • such subsequences or fragments may be generated using the guidance provided by methods known to the skilled artisan to predict protein regions of important functionality.
  • subsequences or fragments may be generated which preserve conserved regions of sequence, as identified using alignment programs or domain-identification programs known to the skilled artisan.
  • conserved regions are important for biological activity, such in silico predictions provide guidance for producing subsequences or fragments with the requisite properties.
  • conserved regions may be identified using, for example, the information provided by the consensus sequences of the present invention. That is, regions which are likely to be important for biological activity are expected to include those identified using either SEQ ID NO: 97 or SEQ ID NO:98, and it is therefore generally advantageous to conserve, or minimally vary, regions identified by methods using these sequences.
  • the Zm-KCPl protein sequence (SEQ ID NO:37) contains the SEQ ID NO:97 consensus sequence at positions 77-93, and the SEQ ID NO:98 consensus sequence at positions 98-112.
  • the proteins encoded by polynucleotides of this embodiment when presented as an immunogen, elicit the production of polyclonal antibodies which specifically bind to a prototype polypeptide such as (but not limited to) a polypeptide encoded by the polynucleotide of sections (A) or (B) above.
  • a protein encoded by a polynucleotide of this embodiment does not bind to antisera raised against the prototype polypeptide when the antisera has been fully immunosorbed with the prototype polypeptide.
  • Methods of making and assaying for antibody binding specificity/affinity are well known in the art.
  • Exemplary immunoassay formats include ELISA, competitive immunoassays, radioimmunoassays, Western blots, indirect immunofluorescent assays and the like.
  • fully immunosorbed and pooled antisera which is elicited to the prototype polypeptide can be used in a competitive binding assay to test the protein.
  • concentration ofthe prototype polypeptide required to inhibit 50% of the binding ofthe antisera to the prototype polypeptide is determined. If the amount ofthe protein required to inhibit binding is less than twice the amount ofthe prototype protein, then the protein is said to specifically bind to the antisera elicited to the immunogen.
  • the proteins ofthe present invention embrace allelic variants, conservatively modified variants, and minor recombinant modifications to a prototype polypeptide.
  • a polynucleotide ofthe present invention optionally encodes a protein having a molecular weight as the non-glycosylated protein within 20% ofthe molecular weight ofthe full-length non-glycosylated polypeptides ofthe present invention.
  • Molecular weight can be readily determined by SDS-PAGE under reducing conditions.
  • the molecular weight is within 15%) of a full length polypeptide ofthe present invention, more preferably within 10%> or 5%, and most preferably within 3%, 2%, or 1% of a full length polypeptide ofthe present invention.
  • the polynucleotides of this embodiment will encode a protein having a specific enzymatic activity at least 50%, 60%>, 70%), 80%>, or 90% of a cellular extract comprising the native, endogenous full-length polypeptide ofthe present invention.
  • the proteins encoded by polynucleotides of this embodiment will optionally have a substantially similar affinity constant (K m ) and/or catalytic activity ⁇ i.e., the microscopic rate constant, k ca t) as the native endogenous, full-length protein.
  • K m affinity constant
  • catalytic activity ⁇ i.e., the microscopic rate constant, k ca t
  • Proteins of this embodiment can have a k cat /K m value at least 10%) of a full-length polypeptide ofthe present invention as determined using the endogenous substrate of that polypeptide.
  • the k cat /K m value will be at least 20%, 30%, 40%, 50%, and most preferably at least 60%, 70%, 80%, 90%, or 95% the k cat /K m value ofthe full-length polypeptide ofthe present invention. Determination of k cat , K m , and k ca t/K m can be determined by any number of means well known to those of skill in the art.
  • the initial rates ⁇ i.e., the first 5%> or less ofthe reaction can be determined using rapid mixing and sampling techniques ⁇ e.g., continuous-flow, stopped-flow, or rapid quenching techniques), flash photolysis, or relaxation methods ⁇ e.g., temperature jumps) in conjunction with such exemplary methods of measuring as spectrophotometry, spectrofluorimetry, nuclear magnetic resonance, or radioactive procedures.
  • Kinetic values are conveniently obtained using a Lineweaver-Burk or Eadie-Hofstee plot.
  • polynucleotides Complementary to the Polynucleotides of(A)-(E)
  • the present invention provides isolated nucleic acids comprising polynucleotides complementary to the polynucleotides of sections A-E, above.
  • complementary sequences base pair throughout the entirety of their length with the polynucleotides of sections (A)-(E) ⁇ i.e., have 100% sequence identity over their entire length).
  • Complementary bases associate through hydrogen bonding in double stranded nucleic acids. For example, the following base pairs are complementary: guanine and cytosine; adenine and thymine; and adenine and uracil.
  • the present invention provides isolated nucleic acids comprising polynucleotides which comprise at least 15 contiguous bases from the polynucleotides of sections (A) (B), (C), (D), (E), or (F) ⁇ i.e., sections (A) - (F), as discussed above).
  • a subsequence of a KCP-like nucleotide sequence may encode a biologically active portion of a KCP-like protein, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed elsewhere herein.
  • Subsequences of a KCP-like nucleotide sequence that are useful as hybridization probes or PCR primers generally need not encode a biologically active portion of a KCP-like protein.
  • polynucleotides ofthe present invention are inclusive of polynucleotides comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220,
  • the number of such subsequences encoded by a polynucleotide ofthe instant embodiment can be any integer selected from the group consisting of from 1 to 1000, such as 2, 3, 4, or 5.
  • the subsequences can be separated by any integer of nucleotides from 1 to the number of nucleotides in the sequence such as at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides.
  • Subsequences can be made by in vitro synthetic, in vitro biosynthetic, or in vivo recombinant methods.
  • subsequences can be made by nucleic acid amplification.
  • nucleic acid primers will be constructed to selectively hybridize to a sequence (or its complement) within, or co-extensive with, the coding region.
  • the subsequences ofthe present invention can comprise structural characteristics ofthe sequence from which it is derived.
  • the subsequences can lack certain structural characteristics ofthe larger sequence from which it is derived such as a poly (A) tail.
  • a subsequence from a polynucleotide encoding a polypeptide having at least one linear epitope in common with a prototype polypeptide sequence as provided in (a), above may encode an epitope in common with the prototype sequence.
  • the subsequence may not encode an epitope in common with the prototype sequence but can be used to isolate the larger sequence by, for example, nucleic acid hybridization with the sequence from which it is derived.
  • Subsequences can be used to modulate or detect gene expression by introducing into the subsequences compounds which bind, intercalate, cleave and/or crosslink to nucleic acids.
  • exemplary compounds include acridine, psoralen, phenanthroline, naphthoquinone, daunomycin or chloroethylaminoaryl conjugates.
  • variants are intended substantially similar sequences.
  • conservative variants include those sequences that, because ofthe degeneracy ofthe genetic code, encode the amino acid sequence of one ofthe KCP- like polypeptides ofthe invention.
  • Naturally occurring allelic variants such as these can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques as outlined below.
  • Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis, but which still encode a protein ofthe invention.
  • variants of a particular nucleotide sequence ofthe invention will have at least about 40%, 50%, 60%, 65%, 70%, generally at least about 75%, 80%, 85%, preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, and more preferably at least about 98%o, 99%) or more sequence identity to that particular nucleotide sequence as determined by sequence alignment programs described elsewhere herein using default parameters.
  • the present invention provides an isolated polynucleotide from a full-length enriched cDNA library having the physico-chemical property of selectively hybridizing to a polynucleotide of sections (A), (B), (C), (D), (E), (F), (G), or (H) as discussed above.
  • Methods of constructing full-length enriched cDNA libraries are known in the art and discussed briefly below.
  • the cDNA library comprises at least
  • the cDNA library can be constructed from a variety of tissues from a monocot or dicot at a variety of developmental stages. Exemplary species include maize, wheat, rice, canola, soybean, cotton, sorghum, sunflower, alfalfa, oats, sugar cane, millet, barley, and rice.
  • Methods of selectively hybridizing, under selective hybridization conditions, a polynucleotide from a full-length enriched library to a polynucleotide ofthe present invention are known to those of ordinary skill in the art. Any number of stringency conditions can be employed to allow for selective hybridization.
  • the stringency allows for selective hybridization of sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, up to 100% sequence identity over the length ofthe hybridized region.
  • Full-length enriched cDNA libraries can be normalized to increase the representation of rare sequences.
  • the present invention provides an isolated polynucleotide made by the process of: 1) providing a full-length enriched nucleic acid library; and 2) selectively hybridizing the polynucleotide to a polynucleotide of sections (A), (B), (C), (D), (E), (F), (G), (H), or (I) as discussed above, and thereby isolating the polynucleotide from the nucleic acid library.
  • Full-length enriched nucleic acid libraries are constructed and selective hybridization conditions are used, as discussed below. Such techniques, as well as nucleic acid purification procedures, are well known in the art.
  • a polynucleotide of sections (A)-(H) can be immobilized to a solid support such as a membrane, bead, or particle. See, e.g., U.S. Patent No. 5,667,976.
  • the polynucleotide product ofthe present process is selectively hybridized to an immobilized polynucleotide and the solid support is subsequently isolated from non-hybridized polynucleotides by methods including, but not limited to, centrifugation, magnetic separation, filtration, electrophoresis, and the like. Construction of Nucleic Acids
  • the isolated nucleic acids ofthe present invention can be made using standard recombinant methods, synthetic techniques, or combinations thereof.
  • the polynucleotides ofthe present invention will be cloned, amplified, or otherwise constructed from a monocot.
  • the nucleic acids may conveniently comprise sequences in addition to a polynucleotide ofthe present invention.
  • a multi-cloning site comprising one or more endonuclease restriction sites may be inserted into the nucleic acid to aid in isolation ofthe polynucleotide.
  • translatable sequences may be inserted to aid in the isolation ofthe translated polynucleotide ofthe present invention.
  • a hexa-histidine marker sequence provides a convenient means to purify the proteins ofthe present invention.
  • a polynucleotide ofthe present invention can be attached to a vector, adapter, or linker for cloning and/or expression of a polynucleotide ofthe present invention.
  • nucleic acid ofthe present invention less the length of its polynucleotide ofthe present invention is less than 20 kilobase pairs, often less than 15 kb, and frequently less than 10 kb.
  • Use of cloning vectors, expression vectors, adapters, and linkers is well known and extensively described in the art. For a description of various nucleic acids see, for example, Stratagene Cloning Systems, Catalogs 1999 (La Jolla, CA); and, Amersham Life Sciences, Inc, Catalog '99 (Arlington Heights, IL).
  • RNA, cDNA, genomic DNA, or a hybrid thereof can be obtained from plant biological sources using any number of cloning methodologies known to those of skill in the art.
  • oligonucleotide probes which selectively hybridize under stringent conditions to the polynucleotides ofthe present invention are used to identify the desired sequence in a cDNA or genomic DNA library. Techniques for the isolation of RNA and construction of cDNA and genomic libraries are well known to those of ordinary skill in the art.
  • Enriched full-length cDNA libraries are constructed to comprise at least 60%, and more preferably at least 70%>, 80%), 90%> or 95% full-length inserts amongst clones containing inserts.
  • the length of insert in such libraries can be at least 2,3, 4, 5, 6, 7, 8, 9, 10 or more kilobase pairs.
  • Nectors to accommodate inserts of these sizes are known in the art and available commercially. See, e.g., Stratagene's lambda ZAP Express (cD ⁇ A cloning vector with 0 to 12 kb cloning capacity).
  • a non-normalized cD ⁇ A library represents the mR ⁇ A population ofthe tissue it was made from. Since unique clones are out-numbered by clones derived from highly expressed genes their isolation can be laborious. Normalization of a cDNA library is the process of creating a library in which each clone is more equally represented. Construction of normalized libraries is described in Ko (1990) Nucl. Acids. Res. 18(19) -.57 5-5711; Patanjali et al. (1991) Proc. Natl. Acad. U.S.A. 55:1943-1947; U.S. Patent Nos. 5,482,685, 5,482,845, and 5,637,685.
  • genomic libraries large segments of genomic DNA are generated by fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector.
  • the cDNA or genomic library can be screened using a probe based upon the sequence of a polynucleotide ofthe present invention such as those disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species. Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either or both ofthe hybridization and the wash medium can be stringent.
  • the nucleic acids of interest can also be amplified from nucleic acid samples using amplification techniques. For instance, polymerase chain reaction (PCR) technology can be used to amplify the sequences of polynucleotides ofthe present invention and related genes directly from genomic DNA or cDNA libraries.
  • PCR polymerase chain reaction
  • PCR and other in vitro amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence ofthe desired mRNA in samples, for nucleic acid sequencing, or for other purposes.
  • the T4 gene 32 protein (Boehringer Mannheim) can be used to improve yield of long PCR products.
  • PCR-based screening methods have been described. Wilfinger et al. (1997) BioTechniques 22(3) :481-486 describe a PCR-based method in which the longest cDNA is identified in the first step so that incomplete clones can be eliminated from study. Such methods are particularly effective in combination with a full-length cDNA construction methodology, above.
  • the isolated nucleic acids ofthe present invention can also be prepared by direct chemical synthesis by methods such as the phosphotriester method of Narang et al. (1979) Meth. Enzymol. 68:90-99; the phosphodiester method of Brown et al. (1979) Meth. Enzymol. (55:109-151; the diethylphosphoramidite method of Beaucage et al. (1981) Tetra. Lett. 22:1859-1862; the solid phase phosphoramidite triester method described by Beaucage and Caruthers (1981) Eetra. Letts.
  • the KCP-like sequences ofthe invention are provided in expression cassettes for expression in the plant of interest.
  • the cassette will include 5' and 3' regulatory sequences operably linked to a KCP-like sequence ofthe invention.
  • operably linked is intended a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription ofthe DNA sequence corresponding to the second sequence.
  • operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.
  • the cassette may additionally contain at least one additional gene to be cotransformed into the organism. Alternatively, the additional gene(s) can be provided on multiple expression cassettes.
  • Such an expression cassette is provided with a plurality of restriction sites for insertion ofthe KCP-like sequence to be under the transcriptional regulation ofthe regulatory regions.
  • the expression cassette may additionally contain selectable marker genes.
  • the expression cassette will include in the 5 '-3' direction of transcription, a transcriptional and translational initiation region, a KCP-like sequence ofthe invention, and a transcriptional and translational termination region functional in plants.
  • the transcriptional initiation region, the promoter may be native or analogous or foreign or heterologous to the plant host. Additionally, the promoter may be the natural sequence or alternatively a synthetic sequence. By “foreign" is intended that the transcriptional initiation region is not found in the native plant into which the transcriptional initiation region is introduced.
  • a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence. While it may be preferable to express the sequences using heterologous promoters, the native promoter sequences may be used. Such constructs would change expression levels of KCP-like polypeptides in the plant or plant cell. Thus, the phenotype ofthe plant or plant cell is altered.
  • the termination region may be native with the transcriptional initiation region, may be native with the operably linked DNA sequence of interest, or may be derived from another source.
  • Convenient termination regions are available from the Ti- plasmid of J. tumefaciens, such as the octopine synthase and nopaline synthase termination regions. See also Guerineau et al. (1991) Mol. Gen. Genet. 262:141-144; Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) Genes Dev. 5:141-149; Mogen et al. (1990) Plant Cell 2:1261-1272; Munroe et al.
  • the gene(s) may be optimized for increased expression in the transformed plant. That is, the genes can be synthesized using plant-preferred codons for improved expression. See, for example, Campbell and Gowri (1990) Plant Physiol. 92:1-11 for a discussion of host-preferred codon usage. Methods are available in the art for synthesizing plant-preferred genes. See, for example, U.S. Patent Nos. 5,380,831, and 5,436,391, and Murray et al. (1989) Nucleic Acids Res. 77:477-498, herein incorporated by reference.
  • Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression.
  • the G-C content ofthe sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.
  • the expression cassettes may additionally contain 5' leader sequences in the expression cassette construct.
  • leader sequences can act to enhance translation.
  • Translation leaders are known in the art and include: picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5' noncoding region) (Elroy-Stein et al. (1989) Proc. Natl. Acad. Sci. USA 5(5:6126-6130); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus) (Gallie et al.
  • MCMV chlorotic mottle virus leader
  • the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame.
  • adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like.
  • in vitro mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and transversions may be involved.
  • Plant expression vectors may include (1) a cloned plant gene under the transcriptional control of 5' and 3' regulatory sequences and (2) a dominant selectable marker. Such plant expression vectors may also contain, if desired, a promoter regulatory region ⁇ e.g., one conferring inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-selective/preferred expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.
  • a promoter regulatory region e.g., one conferring inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-selective/preferred expression
  • a number of promoters can be used in the practice ofthe invention.
  • a plant promoter fragment can be employed which will direct expression of a polynucleotide of the present invention in all tissues of a regenerated plant.
  • Such promoters are referred to herein as "constitutive" promoters and are active under most environmental conditions and stated of development or cell differentiation.
  • constitutive promoters include the cauliflower mosaic virus (CaMN) 35S transcription initiation region, the 1'- or 2'- promoter derived from T-D ⁇ A of Agrobacterium tumefaciens, the ubiquitin 1 promoter (Christensen et al. (1992) Plant Mol Biol 75:675-689; Bruce et al.
  • WO 99/43797 which include the histone H2B, metallothionein, alpha-tubulin 3, elongation factor efla, ribosomal protein rps8, chlorophyll a/b binding protein, and glyceraldehyde-3 -phosphate dehydrogenase promoters, and other transcription initiation regions from various plant genes known to those of skill.
  • weak promoters will be used. It is recognized that weak inducible promoters may be used. Additionally, either a weak constitutive or a weak tissue specific promoter may be used. Generally, by "weak promoter" is intended a promoter that drives expression of a coding sequence at a low level. By low level is intended at levels of about 1/1000 transcripts to about 1/100,000 transcripts to about 1/500,000 transcripts. Alternatively, it is recognized that weak promoters also encompass promoters that are expresses in only a few cells and not in others to give a total low level of expression. Such weak constitutive promoters include, for example, the core promoter ofthe Rsyn7 (PCT Publication No.
  • WO 97/44756 the core 35S CaMV promoter, and the like.
  • a promoter is expressed at unacceptably high levels, portions ofthe promoter sequence can be deleted or modified to decrease expression levels.
  • the transgenic plants will show a variety in performance, from high expression to low expression. Factors such as chromosomal position effect, cosuppression, and the like will affect the expression ofthe polynucleotide.
  • the plant promoter can direct expression of a polynucleotide of the present invention under environmental control.
  • promoters are referred to here as "inducible" promoters.
  • Environmental conditions that may effect transcription by inducible promoters include pathogen attack, anaerobic conditions, or the presence of light.
  • inducible promoters are the Adhl promoter, which is inducible by hypoxia or cold stress, the Hsp70 promoter, which is inducible by heat stress, and the PPDK promoter, which is inducible by light.
  • pathogen-inducible promoters include those from proteins, which are induced following infection by a pathogen; e.g., PR proteins, SAR proteins, beta-l,3-glucanase, chitinase, etc. See, for example, Redolfi et al. (1983) Meth J. Plant Pathol 5P:245-254; Uknes et al. (1992) The Plant Cell 4:645-656; Van Loon (1985) Plant Mol. Virol. 4:111-116; PCT Publication No. WO 99/43819.
  • promoters that are expressed locally at or near the site of pathogen infection. See, for example, Marineau et al. (1987) Plant Mol. Biol. P:335- 342; Matton et al. (1987) Molecular Plant-Microbe Interactions 2:325-342; Somssich et al. (1986) Proc. Natl. Acad. Sci. USA 53:2427-2430; Somssich et al. (1988) Mol. Gen. Genetics 2:93-98; Yang (1996) Proc. Natl. Acad. Sci. USA
  • Such wound-inducible promoter include potato proteinase inhibitor (pin II) gene (Ryan (1990) Annu Rev Phytopath 25:425-449; Duan et al. (1996) Nat Biotech 74:494-498); wunl and wun 2, US Patent No. 5,428,148; winl and win2 (Stanford et al. (1989) Mol. Gen. Genet. 215:200-208); systemin (McGurl et al. (1992) Science 225:1570-1573); WIP1 (Rohmeier et al. (1993) Plant Mol Biol 22:783-792; Eckelkamp et al. (1993) FEB Letters 323:73-76); MPI gene (Cordero et al. (1994) The Plant J. 6(2):141-150); and the like, herein incorporated by reference.
  • pin II potato proteinase inhibitor
  • promoters under developmental control include promoters that initiate transcription only or preferentially in certain tissues, such as leaves, roots, fruit, seeds, or flowers.
  • Exemplary promoters include the anther-specific promoter 5126 (U.S. Patent Nos. 5,689,049 and 5,689,051), glob-1 promoter, and gamma-zein promoter.
  • An exemplary promoter for leaf- and stalk-preferred expression is MS8-15 (PCT Publication No. WO 98/00533).
  • seed-preferred promoters include, but are not limited to, 27 kD gamma zein promoter and waxy promoter (Boronat et ⁇ l (1986) Plant Sci.
  • Promoters that express in the embryo, pericarp, and endosperm are disclosed in U.S. Application Nos. 60/097,233 (filed August 20, 1998) and 60/098,230 (filed August 28, 1998), both hereby incorporated by reference.
  • the operation of a promoter may also vary depending on its location in the genome. Thus, a developmentally-regulated promoter may become fully or partially constitutive in certain locations. A developmentally-regulated promoter can also be modified, if necessary, for weak expression.
  • the nucleic acids encoding the KCP-like polypeptides of the invention are operably linked to a promoter as part of an expression cassette, and introduced into a crop plant such that a transgenic plant is formed.
  • a strong constitutive promoter such as the ubiquitin promoter is utilized.
  • the gene's expression is constitutively high and disease- or stress-resistance is constitutively enhanced.
  • the gene may be linked to a tissue-preferred promoter to direct expression to one or more tissues particularly known to be susceptible to a pathogen that is sought to be controlled. Tissue-preferred promoters can also be used to circumvent expression in tissues that are susceptible to food safety concern.
  • the timing of expression can also be manipulated. For example, by judicious choice of promoter, the expression ofthe transgene can be enhanced earlier than that ofthe native gene in response to pathogen attack; thereby resulting in enhanced disease resistance. For pathogens that do not cause induced expression ofthe native gene, again judicious choice of promoter, may result in induced expression of this gene's coding region in response to that pathogen.
  • Both heterologous and non-heterologous ⁇ i.e., endogenous) promoters can be employed to direct expression ofthe nucleic acids ofthe present invention.
  • the nucleic acid construct will comprise a promoter functional in a plant cell, such as in Zea mays, operably linked to a polynucleotide ofthe present invention.
  • Promoters useful in these embodiments include the endogenous promoters driving expression of a polypeptide ofthe present invention.
  • isolated nucleic acids which serve as promoter or enhancer elements can be introduced in the appropriate position (generally upstream) of a non-heterologous form of a polynucleotide ofthe present invention so as to up- or down- regulate expression of a polynucleotide ofthe present invention.
  • endogenous promoters can be altered in vivo by mutation, deletion, and/or substitution (see U.S. Patent No. 5,565,350 and PCT/US93/03868), or isolated promoters can be introduced into a plant cell in the proper orientation and distance from a gene ofthe present invention so as to control the expression ofthe gene.
  • Gene expression can be modulated under conditions suitable for plant growth so as to alter the total concentration and/or alter the composition ofthe polypeptides ofthe present invention in plant cell.
  • the present invention provides compositions, and methods for making, heterologous promoters and/or enhancers operably linked to a native, endogenous ⁇ i.e., non-heterologous) form of a polynucleotide ofthe present invention.
  • polypeptide expression it is generally desirable to include a polyadenylation region at the 3' end of a polynucleotide coding region.
  • the polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA.
  • the 3' end sequence to be added can be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or less preferably from any other eukaryotic gene. It may also be synthetically designed and constructed.
  • An intron sequence can be added to the 5' untranslated region or the coding sequence ofthe partial coding sequence to increase the amount ofthe mature message that accumulates in the cytosol.
  • Inclusion of a spliceable intron in the transcription unit in both plant and animal expression constructs has bee shown to increase gene expression at both the mRNA and protein levels up to 1000-fold. See Buchman and Berg (1988) Mol. Cell Biol 5:4395-4405; Callis et ⁇ /. (1987) Genes Dev. 7:1183- 1200.
  • Such intron enhancement of gene expression is typically greatest when placed near the 5' end ofthe transcription unit.
  • Use ofthe maize introns Adhl-S intron 1, 2, and 6, and the Bronze- 1 intron are known in the art. See generally, The Maize Handbook, Chapter 116, Freeling and Walbot, Eds., Springer, New York (1994).
  • the vector comprising the sequences of a polynucleotide ofthe present invention will typically comprise a marker gene which confers a selectable phenotype on plant cells.
  • the selectable marker gene will encode antibiotic resistance, with suitable genes including genes coding for resistance to the antibiotic spectinomycin (e.g., the aada gene), the streptomycin phosphotransferase (SPT) gene coding for streptomycin resistance, the neomycin phosphotransferase (NPTII) gene encoding kanamycin or geneticin resistance, the hygromycin phosphotransferase (HPT) gene coding for hygromycin resistance, genes coding for resistance to herbicides which act to inhibit the action of acetolactate synthase (ALS), in particular the sulfonylurea-type herbicides (e.g., the acetolactate synthase (ALS) gene containing mutations leading to such resistance in particular the S4 and/or Hr
  • ALS gene encodes resistance to the herbicide chlorsulfuron.
  • selectable marker genes is not meant to be limiting. Any selectable marker gene can be used in the present invention.
  • Typical vectors useful for expression of genes in higher plants are well known in the art and include vectors derived from the tumor-induced (Ti) plasmid of Agrobacterium tumefaciens, described by Rogers et al. (1987) Meth. Enzymol.
  • vectors are plant integrating vectors; upon transformation, the vectors integrate a portion of vector DNA into the genome ofthe host plant.
  • Exemplary A. tumefaciens vectors useful herein are plasmids pKYLX6 and pKYLX7 of Schardl et al (1987) Gene 61:1-11 and Berger et al. (1989) Proc. Natl Acad. Sci. U S.A. 86: 8402-8406.
  • Another useful vector herein is plasmid pBI 101.2 that is available from Clontech Laboratories, Inc. (Palo Alto, CA).
  • antisense constructions complementary to at least a portion ofthe messenger RNA (mRNA) for the KCP-like sequences can be constructed.
  • Antisense nucleotides are constructed to hybridize with the corresponding mRNA. Modifications ofthe antisense sequences may be made as long as the sequences hybridize to and interfere with expression ofthe corresponding mRNA. In this manner, antisense constructions having 70%, preferably 80%), more preferably 85% sequence identity to the corresponding antisense sequences may be used. Furthermore, portions ofthe antisense nucleotides may be used to disrupt the expression ofthe target gene.
  • sequences of at least 50 nucleotides, 100 nucleotides, 200 nucleotides, or greater may be used.
  • this method to modulate expression of endogenous genes, see Sheehg et. al. (1988) Proc. Natl. Acad. Sci. 55:8805-8809, and U.S. Patent No. 4,801,340.
  • the nucleotide sequences ofthe present invention may also be used in the sense orientation to suppress the expression of endogenous genes in plants. Methods for suppressing gene expression in plants using nucleotide sequences in the sense orientation are known in the art.
  • the methods generally involve transforming plants with a DNA construct comprising a promoter that drives expression in a plant operably linked to at least a portion of a nucleotide sequence that corresponds to the transcript ofthe endogenous gene.
  • a nucleotide sequence has substantial sequence identity to the sequence ofthe transcript ofthe endogenous gene, preferably greater than about 65% sequence identity, more preferably greater than i . - - / v,l 58 about 85%) sequence identity, most preferably greater than about 95% sequence identity.
  • Catalytic RNA molecules or ribozymes can also be used to inhibit expression of plant genes. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity ofthe constructs. The design and use of target RNA-specific ribozymes is described in Haseloff et al. (1988) Nature 334:585-591.
  • cross-linking agents, alkylating agents and radical generating species as pendant groups on polynucleotides ofthe present invention can be used to bind, label, detect, and/or cleave nucleic acids.
  • Vlassov et al (1986) Nucleic Acids Res. 74:4065-4076 describe covalent bonding of a single-stranded DNA fragment with alkylating derivatives of nucleotides complementary to target sequences. (A report of similar work by the same group may be found in Knorre et al. (1985) Biochimie 57:785-789).
  • the isolated proteins ofthe present invention comprise a polypeptide having at least 10 amino acids encoded by any one ofthe polynucleotides ofthe present invention as discussed more fully, above, or polypeptides which are conservatively modified variants thereof.
  • the proteins ofthe present invention or variants thereof can comprise any number of contiguous amino acid residues from a polypeptide of the present invention, wherein that number is selected from the group of integers consisting of from 10 to the number of residues in a full-length polypeptide ofthe present invention.
  • this subsequence of contiguous amino acids is at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 38, 39, or 40 amino acids in length, often at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids in length.
  • variant protein is intended a protein derived from the native protein by deletion (so-called truncation) or addition of one or more amino acids to the N- terminal and/or C-terminal end ofthe native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein.
  • variant proteins encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity ofthe native protein, that is, KCP-like activity as described herein. Such variants may result from, for example, genetic polymo ⁇ hism or from human manipulation.
  • Biologically active variants of a native KCP-like protein ofthe invention will have at least about 40%, 50%, 60%, 65%>, 70%, generally at least about 75%), 80%>, 85%, preferably at least about 90%>, 91%., 92%., 93%, 94%, 95%, 96%, 97%, and more preferably at least about 98%, 99% or more sequence identity to the amino acid sequence for the native protein as determined by sequence alignment programs described elsewhere herein using default parameters.
  • a biologically active variant of a protein ofthe invention may differ from that protein by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue.
  • the proteins ofthe present invention are also intended to include KCP-like sequences wherein the signal or transit peptide has been removed.
  • KCP-like proteins ofthe present invention are predicted to have such sequences using standard techniques such as, for example, PSORT ("Prediction of Protein Translocation Sites"), or SIGNALP ("Signal Peptide Prediction Analysis") or other known methods.
  • PSORT Prediction of Protein Translocation Sites
  • SIGNALP Synignal Peptide Prediction Analysis
  • these proteins have signal or transit peptides and are targeted for the extracellular space. It may be advantageous to use matured polypeptides in some instances, that is polypeptides where the signal or transit peptide sequence has been cleaved or otherwise removed.
  • candidate anti-microbial proteins are expected to be targetted to the extracellular space, since this is the most likely area where a pathogen will be encountered.
  • the present invention is intended to encompass such sequences .
  • the present invention includes catalytically active polypeptides ofthe present invention (i.e., enzymes).
  • Catalytically active polypeptides have a specific activity of at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% that ofthe native (non-synthetic), endogenous polypeptide.
  • the substrate specificity k cat /K m
  • the K m will be at least 30%, 40%>, or 50%, that ofthe native (non-synthetic), endogenous polypeptide; and more preferably at least 60%>, 70%, 80%), or 90%.
  • Methods of assaying and quantifying measures of enzymatic activity and substrate specificity are well known to those of skill in the art.
  • the proteins ofthe present invention will, when presented as an immunogen, elicit production of an antibody specifically reactive to a polypeptide of the present invention. Further, the proteins ofthe present invention will not bind to antisera raised against a polypeptide ofthe present invention which has been fully immunosorbed with the same polypeptide. Immunoassays for determining binding are well known to those of skill in the art. A preferred immunoassay is a competitive - immunoassay as discussed infra. Thus, the proteins ofthe present invention can be employed as immunogens for constructing antibodies immunoreactive to a protein of the present invention for such exemplary utilities as immunoassays or protein purification techniques.
  • the proteins ofthe invention may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants ofthe KCP-like proteins can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 52:488-492; Kunkel et al. (1987) Methods in Enzymol. 154:367-382; U.S. Patent No. 4,873,192; Walker and Gaastra, eds.
  • the genes and nucleotide sequences ofthe invention include both the naturally occurring sequences as well as mutant forms.
  • the proteins ofthe invention encompass both naturally occurring proteins as well as variations and modified forms thereof. Such variants will continue to possess the desired KCP-like activity.
  • the mutations that will be made in the DNA encoding the variant must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. See, EP Patent Application Publication No. 75,444.
  • the deletions, insertions, and substitutions ofthe protein sequences encompassed herein are not expected to produce radical changes in the characteristics ofthe protein.
  • the effect will be evaluated by routine screening assays. That is, the activity can be evaluated by determining the KCP-like properties ofthe sequence or polypeptide which has been deleted, inserted or substituted as described herein. Such properties include, for example, anti-microbial activity. Assays for measuring antimicrobial or anti-pathogenic activity are described elsewhere herein.
  • variant nucleotide sequences and proteins also encompass sequences and proteins derived from a mutagenic and recombinogenic procedure such as DNA shuffling. With such a procedure, one or more different
  • KCP-like coding sequences can be manipulated to create a new KCP-like possessing the desired properties.
  • libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising sequence regions that have substantial sequence identity and can be homologously recombined in vitro or in vivo.
  • nucleic acids ofthe present invention may express a protein of the present invention in a recombinantly engineered cell such as bacterial, yeast, insect, mammalian, or preferably plant cells.
  • a recombinantly engineered cell such as bacterial, yeast, insect, mammalian, or preferably plant cells.
  • the cells produce the protein in a non- natural condition (e.g., different from the natural condition in quantity, composition, location, and/or time), because they have been genetically altered through human intervention to do so.
  • the expression of isolated nucleic acids encoding a protein ofthe present invention will typically be achieved by operably linking, for example, the DNA or cDNA to a promoter (which is either constitutive or regulatable), followed by inco ⁇ oration into an expression vector.
  • the vectors can be suitable for replication and integration in either prokaryotes or eukaryotes.
  • Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation ofthe expression ofthe DNA encoding a protein of the present invention.
  • expression vectors which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator.
  • a strong promoter to direct transcription
  • a ribosome binding site for translational initiation to translational initiation
  • a transcription/translation terminator to facilitate the cloning, expression, or inco ⁇ oration ofthe targeting molecule into a fusion protein.
  • modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly
  • Prokaryotic cells may be used as hosts for expression. Prokaryotes most frequently are represented by various strains of E. coli; however, other microbial strains may also be used. Commonly used prokaryotic control sequences (which are defined herein to include promoters for transcription initiation, optionally with an operator and ribosome binding sequences) include such commonly used promoters as the beta lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al. (1977) N ⁇ twre 198:1056), the tryptophan (t ⁇ ) promoter system (Goeddel et al. (1980) Nucleic Acids Res.
  • D ⁇ A vectors transfected in E coli are also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol .
  • the vector is selected to allow introduction into the appropriate host cell.
  • Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with naked phage vector D ⁇ A. If a plasmid vector is used, the bacterial cells are transfected with the plasmid vector D ⁇ A. Expression systems for expressing a protein ofthe present invention are available using Bacillus spp. and Salmonella (Palva et al. (1983) Gene 22:229-235; Mosbach, et al. (1983) Nature 302:543-545).
  • eukaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells
  • yeast eukaryotic expression systems
  • insect cell lines eukaryotic systems
  • plant and mammalian cells eukaryotic systems
  • a polynucleotide ofthe present invention can be expressed in these eukaryotic systems.
  • transformed/transfected plant cells as discussed infra, are employed as expression systems for production ofthe proteins ofthe instant invention. Synthesis of heterologous proteins in yeast is well known. Sherman, F., et al
  • yeasts Two widely utilized yeasts for production of eukaryotic proteins are Saccharomyces cerevisiae and Pichia pastoris. Nectors, strains, and protocols for expression in Saccharomyces and Pichi ⁇ are known in the art and available from commercial suppliers (e.g., Invitrogen). Suitable vectors usually have expression control sequences such as promoters (including 3-phosphoglycerate kinase or alcohol oxidase) and an origin of replication, termination sequences and the like as desired.
  • promoters including 3-phosphoglycerate kinase or alcohol oxidase
  • a protein ofthe present invention once expressed, can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysate.
  • the monitoring ofthe purification process can be accomplished by using Western blot techniques or radioimmunoassay of other standard immunoassay techniques.
  • the sequences encoding proteins ofthe present invention can also be ligated to various expression vectors for use in transfecting cell cultures of, for instance, mammalian, insect, or plant origin.
  • Illustrative cell cultures useful for the production ofthe peptides are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells, although mammalian cell suspensions may also be used.
  • Suitable host cell lines capable of expressing intact proteins have been developed in the art and include the HEK293, BHK21, and CHO cell lines.
  • Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMN promoter, a HSV tk promoter or pgk (phosphoglycerate kinase) promoter), an enhancer (Queen et ⁇ l. (1986) Immunol. Rev. 89:49), and necessary processing information sites, such as ribosome binding sites, R ⁇ A splice sites, polyadenylation sites ⁇ e.g., an SV40 large T-ag polyA addition site), and transcriptional terminator sequences.
  • a promoter e.g., the CMN promoter, a HSV tk promoter or pgk (phosphoglycerate kinase) promoter
  • an enhancer Queen et ⁇ l. (1986
  • Suitable animal cells useful for production of proteins ofthe present invention are available from, for instance, the American Type Culture Collection.
  • Appropriate vectors for expressing proteins ofthe present invention in insect cells are usually derived from the SF9 baculovirus. Suitable insect cell lines include mosquito larvae, silkworm, armyworm, moth and Drosophila cell lines such as a Schneider cell line (see Schneider (1987) J. Embryol Exp. Morphol 27:353-365).
  • yeast when higher animal or plant host cells are employed, polyadenylation or transcription terminator sequences are typically inco ⁇ orated into the vector.
  • An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing ofthe transcript may also be included.
  • splicing sequence is the VP1 intron from SV40 (Sprague et al. (1983) J. Virol. 45:773-781).
  • gene sequences to control replication in the host cell may be inco ⁇ orated into the vector such as those found in bovine papilloma virus type-vectors (see Saveria-Campo, "Bovine Papilloma Virus DNA: A Eukaryotic Cloning Vector," in DNA Cloning Vol. II a Practical Approach, D.M. Glover, ed., IRL Press, Arlington, Virginia, pp. 213- 238 (1985)).
  • the method of transformation/transfection is not critical to the instant invention; various methods of transformation or transfection are currently available. As newer methods are available to transform crops or other host cells they may be directly applied. Accordingly, a wide variety of methods have been developed to insert a DNA sequence into the genome of a host cell to obtain the transcription and/or translation ofthe sequence to effect phenotypic changes in the organism. Thus, any method which provides for effective transformation and/or transfection may be employed.
  • the genes ofthe present invention can be used to transform any plant. In this manner, genetically modified plants, plant cells, plant tissue, seed, and the like can be obtained. Transformation protocols may vary depending on the type of plant cell targeted for transformation, i.e. monocot or dicot. Suitable methods of transforming plant cells include microinjection (Crossway et al. (1986) BioTechniques 4:320-334), electroporation (Riggs et al. (1986) Proc. Natl. Acad. Sci. USA 53:5602-5606), Agrobacterium mediated transformation (Hinchee et al. (1988) Biotechnology 6: 15- 921; U.S. Patent No. 5,981,840 (maize); U.S. PatentNo.
  • the methods ofthe invention do not depend on a particular method for introducing a nucleotide construct to a plant, only that the nucleotide construct gains access to the interior of at least one cell ofthe plant.
  • Methods for introducing nucleotide constructs into plants are known in the art including, but not limited to, stable transformation methods, transient transformation methods, and virus-mediated methods.
  • stable transformation is intended that the nucleotide construct introduced into a plant integrates into the genome ofthe plant and is capable of being inherited by progeny thereof.
  • transient transformation is intended that a nucleotide construct introduced into a plant does not integrate into the genome ofthe plant.
  • the nucleotide constructs ofthe invention may be introduced into plants by contacting plants with a virus or viral nucleic acids. Generally, such methods involve inco ⁇ orating a nucleotide construct ofthe invention within a viral DNA or RNA molecule.
  • a KCP-like protein ofthe invention may be initially synthesized as part of a viral polyprotein, which later may be processed by proteolysis in vivo or in vitro to produce the desired recombinant protein.
  • promoters ofthe invention also encompass promoters utilized for transcription by viral RNA polymerases. Methods for introducing nucleotide constructs into plants and expressing a protein encoded therein, involving viral DNA or RNA molecules, are known in the art. See, for example, U.S. Patent Nos. 5,889,191, 5,889,190, 5,866,785, 5,589,367 and 5,316,931; herein inco ⁇ orated by reference.
  • the cells that have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick et al. (1986) Plant Cell Reports 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having constitutive expression ofthe desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression ofthe desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure expression ofthe desired phenotypic characteristic has been achieved.
  • the recombinant expression cassette is stably inco ⁇ orated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.
  • mature transgenic plants can be propagated by cuttings or by tissue culture techniques to produce multiple identical plants. Selection of desirable transgenics is made and new varieties are obtained and propagated vegetatively for commercial use.
  • mature transgenic plants can be self-crossed to produce a homozygous inbred plant. The inbred plant produces seed containing the newly introduced heterologous nucleic acid. These seeds can be grown to produce plants having the selected phenotype.
  • Parts obtained from the regenerated plant are included in the invention, provided that these parts comprise cells comprising the isolated nucleic acid ofthe present invention. Progeny, variants, and mutants ofthe regenerated plants are also included within the scope of the invention, provided that these parts comprise the introduced nucleic acid sequences.
  • a preferred embodiment is a transgenic plant that is homozygous for the added heterologous nucleic acid, i.e., a transgenic plant that contains two added nucleic acid sequences, one gene at the same locus on each chromosome of a chromosome pair.
  • a homozygous transgenic plant can be obtained by sexually mating ("selfing") a heterozygous transgenic plant that contains a single added heterologous nucleic acid, germinating some ofthe seed produced, and analyzing the resulting plants produced for altered expression of a polynucleotide ofthe present invention relative to a control plant (i.e., native, non-transgenic). Backcrossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated.
  • Animal and lower eukaryotic host cells are competent or rendered competent for transfection by various means.
  • the transfected cells are cultured by means well known in the art. See Kuchler, R.J., Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc (1997).
  • the present invention further provides a method for modulating ⁇ i.e., increasing or decreasing) the concentration or composition ofthe polypeptides ofthe present invention in a plant or part thereof.
  • Increasing or decreasing the concentration and/or the composition of polypeptides in a plant can effect modulation.
  • increasing the ratio of polypeptides ofthe invention to native polypeptides can affect modulation.
  • the method comprises: introducing a polynucleotide ofthe present invention into a plant cell with a recombinant expression cassette as described above to obtain a transformed plant cell, culturing the transformed plant cell under appropriate growing conditions, and inducing or repressing expression of a polynucleotide ofthe present invention in the plant for a time sufficient to modulate concentration and/or composition of polypeptides in the plant or plant part.
  • the content and/or composition of polypeptides ofthe present invention in a plant may be modulated by altering, in vivo or in vitro, the promoter of a gene to up- or down- regulate gene expression.
  • the coding regions of native genes ofthe present invention can be altered via substitution, addition, insertion, or deletion to decrease activity ofthe encoded enzyme. See U.S. Patent No. 5,565,350 and PCT/US93/03868.
  • an isolated nucleic acid comprising a promoter sequence e.g., a vector
  • a plant cell comprising the promoter operably linked to a polynucleotide ofthe present invention is identified and selected by means known to those of skill in the art (such as, but not limited to, Southern blot, DNA sequencing, or PCR analysis using primers specific to the promoter and to the gene and detecting amplicons produced therefrom).
  • a plant or plant part altered or modified by the foregoing embodiments is grown under appropriate conditions for a time sufficient to modulate the concentration and/or composition of polypeptides of the present invention in the plant.
  • Appropriate growth conditions for transformed plant cells, plant parts, and plants are well known in the art and are discussed briefly elsewhere herein.
  • concentration or composition is increased or decreased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%., 85%, 90%, 95%, or 100%. relative to a native control plant, plant part, or cell lacking the aforementioned recombinant expression cassette.
  • Modulation in the present invention may occur during and/or subsequent to growth ofthe plant to the desired stage of development.
  • Modulating nucleic acid expression temporally and/or in particular tissues can be controlled by employing the appropriate promoter operably linked to a polynucleotide ofthe present invention in, for example, sense or antisense orientation as discussed in greater detail elsewhere herein.
  • Induction of expression of a polynucleotide ofthe present invention can also be controlled by exogenous administration of an effective amount of inducing compound.
  • inducible promoters and inducing compounds which activate expression from these promoters are well known in the art.
  • the polypeptides ofthe present invention are modulated in monocots, particularly maize. Molecular Markers
  • the present invention provides a method of genotyping a plant comprising a polynucleotide ofthe present invention.
  • the plant is a monocot, such as maize or sorghum.
  • Genotyping provides a means of distinguishing homologs of a chromosome pair and can be used to differentiate segregants in a plant population.
  • Molecular marker methods can be used for exemplary applications such as phylogenetic studies, characterizing genetic relationships among crop varieties, identifying crosses or somatic hybrids, localizing chromosomal segments affecting monogenic traits, map-based cloning, and the study of quantitative inheritance. See, e.g. , Plant Molecular Biology: A Laboratory Manual, Chapter 7, Clark, Ed., Springer- Verlag, Berlin (1997).
  • RFLPs restriction fragment length polymo ⁇ hism's
  • the resulting fragments are separated according to size and hybridized with a probe; single-copy probes are preferred. Restriction fragments from homologous chromosomes are thereby revealed. Differences in fragment size among alleles represent an RFLP; thus, the present invention further provides a means to follow segregation of a gene or nucleic acid ofthe present invention as well as chromosomal sequences genetically linked to these genes or nucleic acids using such techniques as RFLP analysis.
  • Linked chromosomal sequences are within 50 centiMorgans (cM), often within 40 or 30 cM, preferably within 20 or 10 cM, more preferably within 5, 4, 3, 2, or 1 cM of a gene ofthe present invention.
  • the nucleic acid probes employed for molecular marker mapping of plant nuclear genomes selectively hybridize (under selective hybridization conditions) to a gene encoding a polynucleotide ofthe present invention.
  • the probes are selected from polynucleotides of the present invention.
  • these probes are cDNA probes or restriction- enzyme-treated genomic clones.
  • the length ofthe probes is discussed in greater detail elsewhere herein, but is typically at least 15 bases in length, more preferably at least 20, 25, 30, 35, 40, or 50 bases in length. Generally, however, the probes are less than about 1 kilobase in length.
  • the probes are single-copy probes that hybridize to a unique locus in the haploid chromosome compliment.
  • Some exemplary restriction enzymes employed in RFLP mapping are EcoRI, EcoRV, and Sst .
  • restriction enzyme includes reference to a composition that recognizes and cleaves at a specific nucleotide sequence, either alone or in conjunction with another composition.
  • the method of detecting an RFLP comprises the steps of: (a) digesting genomic DNA of a plant with a restriction enzyme; (b) hybridizing a nucleic acid probe, under selective hybridization conditions, to a sequence of a polynucleotide of the present invention comprised by said genomic DNA; (c) detecting thereby an RFLP.
  • polymo ⁇ hic (allelic) variants of polynucleotides ofthe present invention can be performed by utilizing molecular marker techniques well known to those of skill in the art, including such techniques as: 1) single stranded conformation analysis (SSCA); 2) denaturing gradient gel electrophoresis (DGG ⁇ ); 3) RNase protection assays; 4) allele-specific oligonucleotides (ASOs); 5) the use of proteins which recognize nucleotide mismatches, such as the E. coli mutS protein; and 6) allele-specific PCR.
  • SSCA single stranded conformation analysis
  • DDGG ⁇ denaturing gradient gel electrophoresis
  • RNase protection assays 4) allele-specific oligonucleotides (ASOs); 5) the use of proteins which recognize nucleotide mismatches, such as the E. coli mutS protein; and 6) allele-specific PCR.
  • ASOs allele-specific oli
  • the present invention further provides a method of genotyping comprising the steps of contacting, under stringent hybridization conditions, a sample suspected of comprising a polynucleotide ofthe present invention with a nucleic acid probe.
  • the sample is a plant sample.
  • the plant sample may be a sample suspected of comprising a maize polynucleotide ofthe present invention (e.g., gene or mRNA).
  • the nucleic acid probe selectively hybridizes under stringent conditions to a subsequence of a polynucleotide ofthe present invention comprising a polymo ⁇ hic marker. Selective hybridization ofthe nucleic acid probe to the polymo ⁇ hic marker nucleic acid sequence yields a hybridization complex. Detection ofthe hybridization complex indicates the presence of that polymo ⁇ hic marker in the sample.
  • the nucleic acid probe comprises a polynucleotide ofthe present invention.
  • polypeptide-encoding segments ofthe polynucleotides ofthe present invention can be modified to alter codon usage.
  • Altered codon usage can be employed to alter translational efficiency and/or to optimize the coding sequence for expression in a desired host such as to optimize the codon usage in a heterologous sequence for expression in maize.
  • Codon usage in the coding regions ofthe polynucleotides ofthe present invention can be analyzed statistically using commercially available software packages, such as "Codon Preference/' available from the University of Wisconsin Genetics Computer Group (see Devereaux et al. (1984) Nucleic Acids Res. 72:387-395) or MacNector 4.1 (Eastman Kodak Co., New Haven, Conn.).
  • the present invention provides a codon usage frequency characteristic ofthe coding region of at least one ofthe polynucleotides ofthe present invention.
  • the number of polynucleotides that can be used to determine a codon usage frequency can be any integer from 1 to the number of polynucleotides ofthe present invention as provided herein.
  • the polynucleotides will be full- length sequences.
  • An exemplary number of sequences for statistical analysis can be at least 1, 5, 10, 20, 50, or 100. Sequence Shufflin
  • sequence shuffling provides methods for sequence shuffling using polynucleotides ofthe present invention, and compositions resulting therefrom. Sequence shuffling is described in PCT Publication No. WO 96/19256. See also, Zhan et al. (1997) Proc. Natl. Acad. Sci. USA P4:4504-4509. Generally, sequence shuffling provides a means for generating libraries of polynucleotides having a desired characteristic for which one of skill can select or screen. Libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides which comprise sequence regions which have substantial identity and can be homologously recombined in vitro or in vivo.
  • the population of sequence- recombined polynucleotides comprises a subpopulation of polynucleotides which possess desired or advantageous characteristics and which can be selected by a suitable selection or screening method.
  • the characteristics can be any property or attribute capable of being selected for or detected in a screening system, and may include properties of: an encoded protein, a transcriptional element, a sequence controlling transcription, RNA processing, RNA stability, chromatin conformation, translation, or other expression property of a gene or transgene, a replicative element, a protein-binding element, or the like, such as any feature which confers a selectable or detectable property.
  • the selected characteristic will be a decreased K m and/or increased K cat over the wild-type protein as provided herein.
  • a protein or polynucleotide generated from sequence shuffling will have a ligand-binding affinity greater than the non-shuffled wild-type polynucleotide.
  • the increase in such properties can be at least 110%, 120%, 130%, 140%), or at least 150% ofthe wild-type value.
  • nucleotide constructs are not intended to limit the present invention to nucleotide constructs comprising DNA.
  • nucleotide constructs particularly polynucleotides and oligonucleotides, comprised of ribonucleotides and combinations of ribonucleotides and deoxyribonucleotides may also be employed in the methods disclosed herein.
  • the nucleotide constructs ofthe present invention encompass all nucleotide constructs that can be employed in the methods ofthe present invention for transforming plants including, but not limited to, those comprised of deoxyribonucleotides, ribonucleotides, and combinations thereof.
  • nucleotide constructs ofthe invention also encompass all forms of nucleotide constructs including, but not limited to, single-stranded forms, double-stranded forms, hai ⁇ ins, stem-and-loop structures, and the like.
  • the methods ofthe invention may employ a nucleotide construct that is capable of directing, in a transformed plant, the expression of at least one protein, or at least one RNA, such as, for example, an antisense RNA that is complementary to at least a portion of an mRNA.
  • a nucleotide construct is comprised of a coding sequence for a protein or an RNA operably linked to 5' and 3' transcriptional regulatory regions.
  • the methods ofthe invention may employ a nucleotide construct that is not capable of directing, in a transformed plant, the expression of a protein or an RNA.
  • methods ofthe present invention do not depend on the inco ⁇ oration ofthe entire nucleotide construct into the genome, only that the plant or cell thereof is altered as a result ofthe introduction ofthe nucleotide construct into a cell.
  • the genome may be altered following the introduction ofthe nucleotide construct into a cell.
  • the nucleotide construct, or any part thereof may inco ⁇ orate into the genome ofthe plant.
  • Alterations to the genome ofthe present invention include, but are not limited to, additions, deletions, and substitutions of nucleotides in the genome. While the methods ofthe present invention do not depend on additions, deletions, or substitutions of any particular number of nucleotides, it is recognized that such additions, deletions, or substitutions comprise at least one nucleotide.
  • nucleotide constructs ofthe invention also encompass nucleotide constructs that may be employed in methods for altering or mutating a genomic nucleotide sequence in an organism, including, but not limited to, chimeric vectors, chimeric mutational vectors, chimeric repair vectors, mixed-duplex oligonucleotides, self-complementary chimeric oligonucleotides, and recombinogenic oligonucleobases.
  • nucleotide constructs and methods of use such as, for example, chimeraplasty, are known in the art.
  • Chimeraplasty involves the use of such nucleotide constructs to introduce site-specific changes into the sequence of genomic DNA within an organism. See, U.S.
  • Polynucleotides and polypeptides ofthe present invention further include those having: (a) a generic sequence of at least two homologous polynucleotides or polypeptides, respectively, ofthe present invention; and (b) a consensus sequence of at least three homologous polynucleotides or polypeptides, respectively, ofthe present invention.
  • the generic sequence ofthe present invention comprises each species of polypeptide or polynucleotide embraced by the generic polypeptide or polynucleotide - sequence, respectively.
  • the individual species encompassed by a polynucleotide having an amino acid or nucleic acid consensus sequence can be used to generate antibodies or produce nucleic acid probes or primers to screen for homologs in other species, genera, families, orders, classes, phyla, or kingdoms.
  • a polynucleotide having a consensus sequence from a gene family of Zea mays can be used to generate antibody or nucleic acid probes or primers to other Gr ⁇ mine ⁇ e species such as wheat, rice, or sorghum.
  • a polynucleotide having a consensus sequence generated from orthologous genes can be used to identify or isolate orthologs of other taxa.
  • a polynucleotide having a consensus sequence will be at least 9, 10, 15, 20, 25, 30, or 40 amino acids in length, or about at least 20, 30, 40, 50, 100, or 150 nucleotides in length.
  • a conservative amino acid substitution can be used to derive a consensus or generic amino acid sequence.
  • no more than 1 or 2 conservative amino acids are substituted for each 10 amino acid length of consensus sequence.
  • Similar sequences used for generation of a consensus or generic sequence include any number and combination of allelic variants ofthe same gene, including orthologous or paralogous sequences as provided herein.
  • similar sequences used in generating a consensus or generic sequence are identified using the BLAST algorithm's smallest sum probability (P(N)).
  • P(N) BLAST algorithm's smallest sum probability
  • a polynucleotide sequence is considered similar to a reference sequence if the smallest sum probability in a comparison ofthe test nucleic acid to the reference nucleic acid is less then about OJ, preferably less than about 0.01, or 0.001, and more preferably less than about 0.0001, or 0.00001.
  • Similar polynucleotides can be aligned and a consensus or generic sequence generated using multiple sequence alignment software available from a number of commercial suppliers such as the Genetics Computer Group's (Madison, WI) PILEUP software, Vector NTI's (North Bethesda, MD) ALIGNX, or Genecode's (Ann Arbor, MI) SEQUENCER. Conveniently, default parameters of such software can be used to generate consensus or generic sequences.
  • Such methods entail, generally, searching a protein database with a pattern, selecting among the protein sequences identified or retrieved and, optionally, further characterizing the selected protein or proteins as KCP-like using other sequence analysis methods, or using biological assays such as have been described previously herein.
  • searching refers to comparing an amino acid sequence pattern with a database of amino acid sequences. Such searches may be performed with a variety of well-known techniques, such as those presented in Example 7 ofthe Experimental section. For example, searching may be performed utilizing PHI- BLAST or PHI-PSI-BLAST under parameters comprising a default Expectation value (E) of 10, a gap opening cost with a default value of 11, and a gap extension cost with a default value of 1, or, additionally, with BLOSUM62 substitution matrix.
  • E Expectation value
  • Pattern refers to an amino acid consensus sequence pattern, as exemplified by SEQ ID NO:97 and SEQ ID NO:98.
  • Database refers to a protein database such as would be well-known to one of ordinary skill, and includes a database of amino acid sequences obtained from protein sequencing as well as presumptive protein sequences obtained by in silico translation of nucleotide sequences. "Selecting,” as used herein refers to choosing one or more ofthe proteins obtained in the search which contain the pattern of interest. As used herein, “further characterizing” refers to further analysis of a selected sequence, which the skilled artisan would know would include a variety of methods, including both computer methods to look for other sequence characteristics indicative of a KCP-like protein, or biological methods, such as assaying the protein corresponding to the identified sequence for KCP-like activity. Such assays have been described elsewhere herein.
  • An exemplar of a method for identifying a KCP-like protein is a method for identifying KCP-like proteins, said method comprising: (a) searching at least one protein database with a pattern selected from the group consisting of: i) a pattern representing a compound having the formula (SEQ ID NO:97) C-X(2)-C-C-X(2)- [CS]-X(1,2)-C-V-P-[PSATK]-[GR]-X(2)-[GAQR], wherein: C is cysteine; X(2) is any two amino acids selected independently from one another; [CS] is one amino acid selected from the group consisting of cysteine and serine; X(l ,2) is X(l) or X(2) wherein X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; V is valine; P is proline; [PSATK] is one amino acid selected from the group consisting of proline, serine, alanine, threonine,
  • the invention also contemplates a computer device capable of implementing the aforementioned methods, and a system for implementing the methods.
  • the invention contemplates a computer device comprising a processing portion capable of searching at least one protein database with a pattern, and a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by at least one formula selected from said group.
  • this computer device may also include a processing portion for further characterizing the selected protein.
  • the skilled artisan would be familiar with the meaning ofthe terms "computer device” and processing portion" as used in the preceding description.
  • the present invention is directed to a computer device capable of implementing a method for identifying KCP- like proteins, said computer device comprising: (a) a processing portion capable of searching at least one protein database with a pattern selected from the group consisting of: i) a pattern representing a compound having the formula (SEQ ID NO:97) C-X(2)-C-C-X(2)-[CS]-X(l,2)-C-V-P-[PSATK]-[GR]-X(2)-[GAQR], wherein: C is cysteine; X(2) is any two amino acids selected independently from one another; [CS] is one amino acid selected from the group consisting of cysteine and serine; X(l,2) is X(l) or X(2) wherein X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; V is valine; P is proline; [PSATK] is one amino acid selected from the group consisting of proline, se
  • X(5) is any five amino acids selected independently from one another
  • X(6) is any six amino acids selected independently from one another
  • X(7) is any seven amino acids selected independently from one another
  • X(8) is any eight amino acids selected independently from one another
  • K is lysine
  • a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by at least one formula selected from said group.
  • the present invention is also directed to a system for implementing the preceding methods, said system comprising: a reference protein database; and a computer device in communication with the reference protein database and comprising a processing portion capable of searching at least one protein database with a pattern, and a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by at least one formula selected from said group.
  • the computer device in this system may also include a processing portion for further characterizing the selected protein.
  • An example of such a system is one for implementing a method for identifying KCP-like proteins, said system comprising: a reference protein database; and a computer device in communication with the reference protein database and comprising: (a) a processing portion capable of searching at least one protein database with a pattern selected from the group consisting of: i) a pattern representing a compound having the formula (SEQ ID NO:97) C-X(2)-C-C-X(2)-[CS]-X(1,2)-C-V-P-[PSATK]-[GR]-X(2)- [GAQR], wherein: C is cysteine; X(2) is any two amino acids selected independently from one another; [CS] is one amino acid selected from the group consisting of cysteine and serine; X(l,2) is X(l) or X(2) wherein X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; V is valine; P is proline; [PSATK] is one amino acid selected from the
  • the present invention is directed to a method for identifying a member of a family of polypeptides, said method comprising: (a) aligning a reference dataset consisting of preselected members of said family; (b) determining a consensus sequence pattern that identifies all said preselected members; (c) searching at least one protein database with said consensus sequence pattern; (d) selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by said pattern; and (e) identifying the selected protein as a member of said family.
  • a computer device capable of implementing a method for identifying a member of a family of polypeptides, said computer device comprising: (a) a processing portion capable of aligning a reference dataset consisting of preselected members of said family; (b) a processing portion capable of determining a consensus sequence pattern that identifies all said preselected members; (c) a processing portion capable of searching at least one protein database with said consensus sequence pattern; (d) a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by said pattern; and (e) a processing portion capable of identifying the selected protein as a member of said family.
  • Another contemplated method ofthe present invention is directed to a system for implementing a method for identifying a member of a family of polypeptides, said system comprising: a reference dataset; and a computer device in communcation with the reference dataset and comprising: (a) a processing portion capable of aligning said reference dataset consisting of preselected members of said family; (b) a processing portion capable of determining a consensus sequence pattern that identifies all said preselected members; (c) a processing portion capable of searching at least one protein database with said consensus sequence pattern; (d) a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by said pattern; and (e) a processing portion capable of identifying the selected protein as a member of said family.
  • Immature maize embryos from greenhouse donor plants are bombarded with a plasmid containing a KCP-like nucleotide sequence operably linked to a ubiquitin promoter and the selectable marker gene PAT (Wohlleben et al. (1988) Gene 70:25- 37), which confers resistance to the herbicide Bialaphos.
  • the selectable marker gene is provided on a separate plasmid. Transformation is performed as follows. Media recipes follow below.
  • the ears are husked and surface sterilized in 30%> Clorox bleach plus 0.5% Micro detergent for 20 minutes and rinsed two times with sterile water.
  • the immature embryos are excised and placed embryo axis side down (scutellum side up), 25 embryos per plate, on 560Y medium for 4 hours and then aligned within the 2.5- cm target zone in preparation for bombardment.
  • a plasmid vector comprising the KCP-like gene operably linked to an ubiquitin promoter is made.
  • This plasmid DNA plus plasmid DNA containing a PAT selectable marker is precipitated onto 1.1 ⁇ m (average diameter) tungsten pellets using a CaCl precipitation procedure as follows:
  • sample plates are bombarded at level #4 in particle gun #HE34-1 or #HE34-2. All samples receive a single shot at 650 psi, with a total often aliquots taken from each tube of prepared particles/DNA.
  • the embryos are kept on 560Y medium for 2 days, then transferred to 560R selection medium containing 3 mg/liter Bialaphos and subcultured every 2 weeks. After approximately 10 weeks of selection, selection- resistant callus clones are transferred to 288J medium to initiate plant regeneration. Following somatic embryo maturation (2-4 weeks), well-developed somatic embryos are transferred to medium for germination and transferred to the lighted culture room. Approximately 7-10 days later, developing plantlets are transferred to 272V hormone- free medium in tubes for 7-10 days until plantlets are well established.
  • Plants are then transferred to inserts in flats (equivalent to 2.5" pot) containing potting soil and grown for 1 week in a growth chamber, subsequently grown an additional 1-2 weeks in the greenhouse, then transferred to classic 600 pots (1.6 gallon) and grown to maturity. Plants are monitored and scored for expression of KCP-like protein. Assays to monitor expression of KCP-like sequences include, for example, Northern and Western analysis and phenotypic assays including enhanced disease resistance.
  • Bombardment and Culture Media Bombardment medium (560 Y) comprises 4.0 g/1 N6 basal salts (SIGMA C-
  • Selection medium comprises 4.0 g/1 N6 basal salts (SIGMA C-1416), 1.0 ml/1 Eriksson's Vitamin Mix (1000X SIGMA-1511), 0.5 mg/1 thiamine HC1, 30.0 g/1 sucrose, and 2.0 mg/12,4-D (brought to volume with D-I H 2 0 following adjustment to pH 5.8 with KOH); 3.0 g/1 Gelrite (added after bringing to volume with D-I H 2 0); and 0.85 mg/1 silver nitrate and 3.0 mg/1 bialaphos(both added after sterilizing the medium and cooling to room temperature).
  • Plant regeneration medium (288J) comprises 4.3 g/1 MS salts (GIBCO 11117- 074), 5.0 ml/1 MS vitamins stock solution (0.100 g nicotinic acid, 0.02 g/1 thiamine HCL, 0.10 g/1 pyridoxine HCL, and 0.40 g/1 glycine brought to volume with polished D-I H 2 0) (Murashige and Skoog (1962) Physiol Plant.
  • Hormone-free medium comprises 4.3 g/1 MS salts (GIBCO l l l l 7-074), 5.0 ml/1 MS vitamins stock solution (0.100 g/1 nicotinic acid, 0.02 g/1 thiamine HCL, 0.10 g/1 pyridoxine HCL, and 0.40 g/1 glycine brought to volume with polished D-I H 2 0), 0.1 g/1 myo-inositol, and 40.0 g/1 sucrose (brought to volume with polished D-I H 2 0 after adjusting pH to 5.6); and 6 g/1 bacto-agar (added after bringing to volume with polished D-I H 2 0), sterilized and cooled to 60° C.
  • Soybean embryos are bombarded with a plasmid containing a KCP-like nucleic acid operably linked to an ubiquitin promoter as follows. To induce somatic embryos, cotyledons 3 - 5 mm in length are dissected from surface-sterilized, immature seeds of the soybean cultivar A2872 and cultured in the light or dark at 26°C on an appropriate agar medium for six to ten weeks. Somatic embryos producing secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos that multiplied as early, globular-staged embryos, the suspensions are maintained as described below.
  • Soybean embryogenic suspension cultures can be maintained in 35 ml of liquid media on a rotary shaker at 150 ⁇ m and 26°C with fiorescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 ml of liquid medium.
  • Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) Nature 327:70-73); U.S. Patent No. 4,945,050).
  • a DuPont Biolistic PDS1000/HE instrument helium retrofit
  • a selectable marker gene that can be used to facilitate soybean transformation is a transgene composed ofthe 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) Nature 373:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from E. coli; Gritz et al. (1983) Gene 25:179-188), and the 3' region ofthe nopaline synthase gene from the T-DNA ofthe Agrobacterium tumefaciens Ti plasmid.
  • the expression cassette comprising the KCP-like sequence operably linked to the promoter can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site ofthe vector carrying the marker gene.
  • Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm Petri dish and the residual liquid removed from the tissue with a pipette.
  • approximately 5-10 plates of tissue are normally bombarded.
  • Membrane rupture pressure is set at 1100 psi, and the chamber is evacuated to a vacuum of 28 inches mercury.
  • the tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.
  • the liquid media may be exchanged with fresh media, and eleven to twelve days post-bombardment with fresh media containing 50 mg/ml hygromycin. This selective media can be refreshed weekly.
  • Green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.
  • the immature embryos are preferably immersed in an Agrobacterium suspension for the initiation of inoculation.
  • the embryos are co- cultured for a time with the Agrobacterium (step 2: the co-cultivation step).
  • the immature embryos are cultured on solid medium following the infection step.
  • an optional "resting" step is contemplated.
  • the embryos are incubated in the presence of at least one antibiotic known to inhibit the growth of Agrobacterium without the addition of a selective agent for plant transformants (step 3: resting step).
  • the immature embryos are cultured on solid medium with antibiotic, but without a selecting agent, for elimination of Agrobacterium and for a resting phase for the infected cells.
  • inoculated embryos are cultured on medium containing a selective agent and growing transformed callus is recovered (step 4: the selection step).
  • the immature embryos are cultured on solid medium with a selective agent resulting in the selective growth of transformed cells.
  • the callus is then regenerated into plants (step 5: the regeneration step), and preferably calli grown on selective medium are cultured on solid medium to regenerate the plants.
  • plant tissue samples were pulverized in liquid nitrogen before the addition of the TRIzol Reagent, and then were further homogenized with a mortar and pestle. Addition of chloroform followed by centrifugation was conducted for separation of an aqueous phase and an organic phase. Total RNA was recovered by precipitation with isopropyl alcohol from the aqueous phase. The selection of poly(A)+ RNA from total RNA was performed using
  • Biotinylated oligo(dT) primers were used to hybridize to the 3' poly(A) tails on mRNA.
  • the hybrids were captured using streptavidin coupled to paramagnetic particles and a magnetic separation stand.
  • the mRNA was washed in highly stringent conditions and eluted with RNase-free deionized water.
  • cDNA synthesis was performed and unidirectional cDNA libraries were constructed using the Superscript Plasmid System (Life Technology, Inc.,
  • the first strand of cDNA was synthesized by priming an oligo(dT) primer containing a Not I site. The reaction was catalyzed by Superscript Reverse Transcriptase II at 45 °C. The second strand of cDNA was labeled with alpha- 32 P-dCTP and a portion ofthe reaction was analyzed by agarose gel electrophoresis to determine cDNA sizes. cDNA molecules smaller than 500 base pairs and unligated adaptors were removed by Sephacryl-S400 chromatography. The selected cDNA molecules were ligated into a pSPORTl vector between the Not/ and Sail sites.
  • Example 5 cD ⁇ A Sequencing and Library Subtraction. Individual colonies were picked and D ⁇ A was prepared either by PCR with
  • D ⁇ A was then cross-linked to the nylon membrane by UN light treatment.
  • Colony hybridization was conducted as described by Sambrook, Fritsch, and
  • cDN A clones derived from rRNA.
  • the image ofthe autoradiography was scanned into an analysis computer and the signal intensity and "cold colony" addresses of each colony was analyzed. Re- arraying of cold colonies from 384 well plates to 96 well plates was conducted using Q-bot. 15
  • Gene identities can be determined by conducting BLAST searches (Basic Local Alignment Search Tool; Altschul etal. (1993) J. Mol Biol. 275:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) under default parameters for similarity to 20 sequences contained in the BLAST "nr" database.
  • the publicly-available NCBI nr database comprises all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release ofthe SWISS-PROT protein sequence database, and the EMBL and DDBJ databases.
  • the . cDNA sequences are analyzed for similarity to all publicly available 25.
  • DNA sequences contained in the "nr” database using the BLASTN algorithm.
  • the DNA sequences ' are translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr” database using the BLASTX algorithm (Gish and States (1993) Nature Genetics 3:266-272).
  • the sequencing data from two or more clones containing overlapping segments 30 of DNA are used to construct contiguous DNA sequences.
  • a search of publicly available databases revealed that a petunia sequence (Q43615) shares 54% identity and 63% similarity with the Zm-KCPl predicted peptide, and a cotton sequence (W15751) shares 44% identity and 52% similarity with the Zm-KCPl predicted peptide.
  • Example 7 Computer-Implemented Methods, and Consensus Patterns (Regular Expressions) that Specifically Identify KCP Gene Family Members
  • the invention encompasses the discovery and analysis of 36 crop plant genes in the KCP family, which are related to the potato antimicrobial peptide snakin.
  • the invention additionally provides computer-implemented methods, and two amino acid consensus sequence patterns (regular expressions 1 and 2) that specifically identify KCP-like gene family members.
  • regular expressions 1 and 2 are useful for identifying a subset of KCP related proteins that are within the family of the KCP-like proteins of the invention.
  • Regular expression 1 has the amino acid sequence consensus pattern:
  • cysteine two amino acids of any type—cysteine— cysteine— two amino acids of any type-cysteine or serine— one or two amino acids of any type— cysteine— valine— proline—pf ⁇ line or serine or alanine or threonine or lysine— glycine or arginine— two amino acids of any type—glycine or alanine or glutamine or arginine.
  • Regular expression 2 has the amino acid sequence consensus pattern: [CS]-[PSQAG]-x(0,2)-C-Y-x(4)-[TNSM]-x(5,8)-K (SEQ ID NO:98). This notation of this expression also follows the protocol referred to above, and designates the following sequence pattern: cysteine or serine— proline or serine or glutamine or alanine or glycine— zero or one or two amino acids of any type— cysteine—tyrosine— four amino acids of any type— threonine or asparagine or serine or methionine— five or six or seven or eight amino acids of any type— lysine.
  • KCP-like reference dataset A reference dataset of KCP-like polypeptide sequences was constructed to test the effectiveness of various candidate regular expressions in identifying KCP-like proteins.
  • This reference dataset consisted ofthe KCP-like polypeptides ofthe invention set forth in SEQ ID NO:37-72, a KCP polypeptide set forth in SEQ ID NO: 73 a novel KCP-like polypeptide (sequence not shown), as well as a set of KCP- like polypeptides identified from public databases by a combination of BLAST and PSI-BLAST.
  • the set of KCP-like polypeptides identified from public databases correspond to those identified in TABLE 1 and set forth in SEQ ID NOS:74-96 respectively.
  • GASA5 gibberellin-regulated protein
  • GASA5-like protein Arabidopsis thalianasp_O80641_O80641 GIBBERELLIN- REGULATED PROTEIN (GASA5)-LIKE. -gi_2982285 gb_AAC32128.1_ (AF051227) GAS A5-like protein [Picea mariana]sp_ O65066_O65066 GASA5-LIKE PROTEIN.
  • -pir_S60229 S60229 gibberellin-regulated protein GASA1 precursor - Arabidopsis thaliana.
  • the method employed for identifying all the KCP sequences was either PHI- BLAST (Pattern Hit Initiated BLAST) or a combination of PHI-BLAST and PSI- BLAST (Position Specific Iteration Blast). See Zhang et al (1998) Nucleic Acids Research 26: 3986-3990.
  • PHI-BLAST and PSI-BLAST were used in combination, the search was done in two rounds, with the first round using PHI- BLAST, and the second round using PSI-BLAST (PHI-PSI-BLAST).
  • the BLOSUM62 substitution matrix was used, as was the default Expectation value (E) of 10. Cost for opening gaps was used with the default value of 11, and the cost to extend a gap was also used with the default value of 1.
  • the PHI-BLAST, PSI-BLAST, or the PHI-PSI-BLAST tandem routine In order to run the PHI-BLAST, PSI-BLAST, or the PHI-PSI-BLAST tandem routine, a designated query sequence was required.
  • the initial default query sequence used to test various candidate regular expressions was Zm-KCPl .
  • the routine was repeated with at least three other query sequences, namely Os-KCP 1 , Ta-KCP 1 and Gm-KCP 1 , that represent breadth and diversity in the KCP-like protein family. Repeating the routine with the additional sequences indicated that the result for a regular expression was independent ofthe KCP-like query sequence used.
  • regular expression 1 corresponds to amino acid positions 77 to 93 of default query sequence Zm-KCPl (SEQ ID NO:37).
  • regular expression 2 corresponds to amino acid positions 98 to 112 of default query sequence Zm-KCPl (SEQ ID NO:37).
  • regular expressions 1 and 2 were tested against an open field dataset, namely the public NR (nonredundant) database.
  • regular expression 1 was able to identify 22 ofthe 23 ofthe above publicly known KCP-like sequences set forth in TABLE 1, when used with the four different query KCP-like sequences (SEQ ID NOS:37, 46, 55 and 95). It is noted that, when using PHI-BLAST, this regular expression did not identify non-KCP sequences; and identified only the 22 KCP sequences (See appendix I for the output). However, when PHI-PSI-BLAST was used, the entire 23/23 publicly known KCP-like sequences (TABLE 1) were identified.
  • tandem PHI-PSI-BLAST is more effective that PHI-BLAST alone for utilizing regular expression 1.
  • additional sequences were also identified with E values below the threshold of 10. These other sequences included distintigrins, mucins, and metallothioproteinases, but not the hemolytic protein kistrin. It should be noted however that their E value scores were markedly less significant than any ofthe 23 core public KCP-like sequences of TABLE 1. The least significant E value score from the PSI-BLAST portion was le-17, and the most significant non-KCP E value score was 0.014 (see appendix II for output). This wide range in the output E value scores indicates that by using PHI-PSI-BLAST as described and in conjunction with regular expression 1, all or nearly all members ofthe KCP-like family can be identified to the exclusion of non-members of this family.
  • both PHI-BLAST and tandem PHI-PSI-BLAST identifies all 23 ofthe public KCP-like genes.
  • a regular expression was designed which was identical to that set forth above, and in SEQ ID NO:98, for regular expression 2, with the exception that a -[TNS]- position was used in place of a -[TNSM]- position.
  • This initial version of regular expression 2 identified all 23 ofthe public KCP-like genes in the reference dataset.
  • tandem PHI-PSI-BLAST the gulf in E value scores between the output E value scores was also large. The least significant KCP E value score from the PSI-BLAST portion was le-18, and the most significant non-KCP E value score was 0.003.
  • Ta-KCP 1 sequence ofthe invention did not exactly match this initial KCP regular expression 2.
  • This Ta-KCP 1 sequence had a methionine at the corresponding -[TNS]- position. Inclusion of methionine as an option at this position does allow for identification of Ta-KCP 1 by regular expression 2 set forth above, and in SEQ ID NO:98.
  • both KCP regular expressions 1 and 2 employed with the methods described here are specific identifiers of members of the KCP gene family. Numerous other regular expressions; including those designed based on twelve conserved cysteines and those including terminal lysine, cysteine, and proline residues. These other regular expressions failed to identify all ofthe KCP-like sequences in the reference dataset.
  • KCP regular expressions 1 and 2 are useful for identifying KCP-like protein family members using tandem PHI-PSI-BLAST. These regular expressions can be used alone or in combination to effect a complete or near complete identification of members of KCP-like family of proteins.
  • the methods ofthe present invention could be used to identify members of any family of proteins. That is, the methods ofthe invention can be used to align a reference dataset consisting of known or preselected members of a family, determining a consensus sequence pattern that identifies all ofthe known or preselected members, searching at least one protein database with this consensus sequence pattern, selecting among the retrieved proteins at least one protein comprising at least one amino acid sequence represented by the pattern; and identifying the selected protein as a member of this family.
  • the methods ofthe present invention can be used to identify one or more subsets of a known family, wherein the subset consists of members the family that are identified by a consensus sequence that identifies all members ofthe subset and excludes other members ofthe family.
  • Query Zm-KCPl, p0118.chsbd73r, FL, Zea mays, proofed (114 letters) Database: nr 485,275 sequences; 152,116,570 total letters Searching 1 occurrence (s) of pattern in query
  • bits Value Significant matches for pattern occurrence 1 at position 98 em I CAA66909.il (X98255) transcriptionally stimulated by gibber... 80

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des acides nucléiques isolés apparentés à KCP et leurs protéines codées. Elle concerne également des méthodes et des compositions se rapportant à la modification d'un acide nucléique apparenté à KCP et/ou à la concentration protéique et/ou à la composition chez des plantes. Elle concerne en outre des cassettes d'expression recombinantes, des cellules hôtes et des plantes transgéniques.
EP01970822A 2000-09-13 2001-09-13 Peptides antimicrobiens et methodes d'utilisation Expired - Lifetime EP1379658B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08020600A EP2039769A3 (fr) 2000-09-13 2001-09-13 Peptides antimicrobiennes et procédés d'utilisation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23256900P 2000-09-13 2000-09-13
US232569P 2000-09-13
US950933 2001-09-11
US09/950,933 US6875907B2 (en) 2000-09-13 2001-09-11 Antimicrobial peptides and methods of use
PCT/US2001/028429 WO2002022821A2 (fr) 2000-09-13 2001-09-13 Peptides antimicrobiens et methodes d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP08020600A Division EP2039769A3 (fr) 2000-09-13 2001-09-13 Peptides antimicrobiennes et procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP1379658A2 true EP1379658A2 (fr) 2004-01-14
EP1379658B1 EP1379658B1 (fr) 2009-01-28

Family

ID=26926132

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01970822A Expired - Lifetime EP1379658B1 (fr) 2000-09-13 2001-09-13 Peptides antimicrobiens et methodes d'utilisation
EP08020600A Withdrawn EP2039769A3 (fr) 2000-09-13 2001-09-13 Peptides antimicrobiennes et procédés d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08020600A Withdrawn EP2039769A3 (fr) 2000-09-13 2001-09-13 Peptides antimicrobiennes et procédés d'utilisation

Country Status (9)

Country Link
US (5) US6875907B2 (fr)
EP (2) EP1379658B1 (fr)
AT (1) ATE421992T1 (fr)
AU (2) AU9078401A (fr)
BR (1) BR0113864A (fr)
CA (1) CA2422041A1 (fr)
DE (1) DE60137587D1 (fr)
MX (1) MXPA03002218A (fr)
WO (1) WO2002022821A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6932980B1 (en) * 2001-01-18 2005-08-23 Richard Sayre Method of making microalgal-based animal foodstuff supplements, microalgal-supplemented animal foodstuffs and method of animal nutrition
WO2001098335A2 (fr) * 2000-06-20 2001-12-27 Phycotransgenics, Llc Algues transgeniques pour administration d'antigenes a un animal
CA2492544A1 (fr) 2002-08-02 2004-02-12 Basf Plant Science Gmbh Modification d'huile de graines par expression d'une cytidyltransferase putative dans des plantes transgeniques
US7301069B2 (en) * 2004-06-30 2007-11-27 Pioneer Hi-Bred International, Inc. Methods of protecting plants from pathogenic fungi and nematodes
US7978669B2 (en) * 2007-05-09 2011-07-12 Cisco Technology, Inc. Methods and apparatus for efficient MPEG transmission over 802.11
US7964774B2 (en) 2008-05-14 2011-06-21 Monsanto Technology Llc Plants and seeds of spring canola variety SCV384196
US7947877B2 (en) 2008-05-14 2011-05-24 Monosanto Technology LLC Plants and seeds of spring canola variety SCV328921
US8829282B2 (en) 2008-05-14 2014-09-09 Monsanto Technology, Llc Plants and seeds of spring canola variety SCV425044
US7935870B2 (en) 2008-05-14 2011-05-03 Monsanto Technology Llc Plants and seeds of spring canola variety SCV354718
WO2010008737A2 (fr) * 2008-06-17 2010-01-21 Pelican Group Holdings, Inc. Dispositifs de manipulation de fluide du type antimicrobien et procédés de fabrication
WO2010005910A2 (fr) * 2008-07-08 2010-01-14 Monarch Labs Llc Pansements et procédés utilisables dans le cadre d'un traitement de débridement par des asticots
AU2010203698B2 (en) 2009-01-06 2016-07-21 C3 Jian, Inc. Targeted antimicrobial moieties
US20100183523A1 (en) * 2009-01-22 2010-07-22 Wagner Richard E Dental composition and method
EP2210582B1 (fr) 2009-01-22 2019-09-18 Solarvest Bioenergy Inc. Composition dentaire comprenant des algues et procédé pour sa préparation
US8071848B2 (en) 2009-06-17 2011-12-06 Monsanto Technology Llc Plants and seeds of spring canola variety SCV218328
US8440891B2 (en) 2009-09-22 2013-05-14 Board of Trustees of the University of Akransas, N.A. Rice cultivar CL 142-AR
US8440892B2 (en) 2009-10-15 2013-05-14 Board Of Trustees Of The University Of Arkansas, N.A. Rice cultivar CL 181-AR
US8143488B2 (en) 2010-02-26 2012-03-27 Monsanto Technoloy LLC Plants and seeds of spring canola variety SCV470336
US8138394B2 (en) 2010-02-26 2012-03-20 Monsanto Technology Llc Plants and seeds of spring canola variety SCV431158
US8148611B2 (en) 2010-02-26 2012-04-03 Monsanto Technology Llc Plants and seeds of spring canola variety SCV453784
US8581048B2 (en) 2010-03-09 2013-11-12 Monsanto Technology, Llc Plants and seeds of spring canola variety SCV119103
US8153865B2 (en) 2010-03-11 2012-04-10 Monsanto Technology Llc Plants and seeds of spring canola variety SCV152154
US8513487B2 (en) 2011-04-07 2013-08-20 Zenon LISIECZKO Plants and seeds of spring canola variety ND-662c
US8513494B2 (en) 2011-04-08 2013-08-20 Chunren Wu Plants and seeds of spring canola variety SCV695971
US8507761B2 (en) 2011-05-05 2013-08-13 Teresa Huskowska Plants and seeds of spring canola variety SCV372145
US8513495B2 (en) 2011-05-10 2013-08-20 Dale Burns Plants and seeds of spring canola variety SCV291489
US8785729B2 (en) 2011-08-09 2014-07-22 Nunhems, B.V. Lettuce variety redglace
US8754293B2 (en) 2011-09-09 2014-06-17 Nunhems B.V. Lettuce variety intred
EP3384938A1 (fr) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Acides nucléiques techniques et leurs procédés d'utilisation
US9380756B2 (en) 2012-01-04 2016-07-05 Nunhems B.V. Lettuce variety multigreen 50
JP2015518705A (ja) 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US8802935B2 (en) 2012-04-26 2014-08-12 Monsanto Technology Llc Plants and seeds of spring canola variety SCV942568
US8878009B2 (en) 2012-04-26 2014-11-04 Monsanto Technology, LLP Plants and seeds of spring canola variety SCV318181
US8835720B2 (en) 2012-04-26 2014-09-16 Monsanto Technology Llc Plants and seeds of spring canola variety SCV967592
US8859857B2 (en) 2012-04-26 2014-10-14 Monsanto Technology Llc Plants and seeds of spring canola variety SCV259778
BR112017006575B1 (pt) 2014-10-01 2023-11-21 Plant Health Care, Inc Peptídeo isolado, polipeptídeo de fusão, composição e métodos de conferir resistência à doença às plantas, de potencializar o crescimento da planta, de aumentar a tolerância da planta ao estresse biótico ou ao estresse abiótico e de modular a sinalização bioquímica da planta
CA2962945A1 (fr) 2014-10-01 2016-04-07 Plant Health Care, Inc. Peptides eliciteurs ayant une boite de reponse hypersensible rompue et utilisation associee
CA2992488A1 (fr) 2015-08-28 2017-03-09 Pioneer Hi-Bred International, Inc. Transformation de plantes mediee par ochrobactrum
AU2016353073A1 (en) 2015-11-10 2018-06-07 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
EP3439682A4 (fr) 2016-04-06 2019-12-25 Plant Healthcare, Inc. Peptides dérivés d'éliciteurs de réponse hypersensible et leur utilisation
BR112018069945A2 (pt) 2016-04-06 2019-02-05 Plant Health Care Inc micróbios benéficos para distribuição de peptídeos ou proteínas efetoras e uso dos mesmos
CN105968177B (zh) * 2016-05-06 2021-06-18 广州大学 香蕉抗菌肽MaSN2及其基因的新应用
CN106632628A (zh) * 2016-09-21 2017-05-10 东北师范大学 植物抗病毒相关蛋白GmSN1及其编码基因和应用
US11890319B2 (en) 2017-01-18 2024-02-06 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US20200165309A1 (en) 2017-05-11 2020-05-28 Los Angeles Biomedical Research Institute at Flarbor-UCLA Medical Center Antimicrobial peptides with alpha-core helices
US11969476B2 (en) 2020-04-03 2024-04-30 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
JPS62291904A (ja) 1986-06-12 1987-12-18 Namiki Precision Jewel Co Ltd 永久磁石の製造方法
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5256648A (en) 1988-01-21 1993-10-26 Yale University Selective inhibition of gene expression by photoactivatable oligonucleotides
US5316931A (en) 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5990387A (en) 1988-06-10 1999-11-23 Pioneer Hi-Bred International, Inc. Stable transformation of plant cells
US5034323A (en) 1989-03-30 1991-07-23 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5667976A (en) 1990-05-11 1997-09-16 Becton Dickinson And Company Solid supports for nucleic acid hybridization assays
CA2083148C (fr) 1990-05-24 2002-01-01 Christopher J. Michejda Bistriazenes en tant qu'agents chimiotherapeutiques
NZ239977A (en) 1990-11-14 1993-08-26 Pioneer Hi Bred Int Transforming plants by the use of agrobacterium
US5932782A (en) 1990-11-14 1999-08-03 Pioneer Hi-Bred International, Inc. Plant transformation method using agrobacterium species adhered to microprojectiles
GB9112300D0 (en) * 1991-06-07 1991-07-24 Ici Plc Biocidal proteins
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW261517B (fr) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
US5543507A (en) 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
US5428148A (en) 1992-04-24 1995-06-27 Beckman Instruments, Inc. N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis
JP3594595B2 (ja) * 1992-11-12 2004-12-02 シンジェンタ リミテッド 殺生物性のキチン結合性蛋白質
IL108241A (en) 1992-12-30 2000-08-13 Biosource Genetics Corp Plant expression system comprising a defective tobamovirus replicon integrated into the plant chromosome and a helper virus
US6069298A (en) * 1993-02-05 2000-05-30 Regents Of The University Of Minnesota Methods and an acetyl CoA carboxylase gene for conferring herbicide tolerance and an alteration in oil content of plants
US5482685A (en) 1993-04-12 1996-01-09 Matsushita Electric Industrial Co., Ltd. Deodorizing apparatus
US5470722A (en) 1993-05-06 1995-11-28 University Of Iowa Research Foundation Method for the amplification of unknown flanking DNA sequence
WO1995000547A1 (fr) 1993-06-22 1995-01-05 E.I. Du Pont De Nemours And Company Composition antimicrobienne comprenant un polymere et un peptide formant des helices amphiphiles du type magainine
US5482845A (en) 1993-09-24 1996-01-09 The Trustees Of Columbia University In The City Of New York Method for construction of normalized cDNA libraries
US5470353A (en) 1993-10-20 1995-11-28 Hollister Incorporated Post-operative thermal blanket
CA2178729A1 (fr) 1993-12-09 1995-06-15 Eric B. Kmiec Composes et procedes pour realiser des mutations dirigees sur le site dans des cellules eucaryotes
US5750868A (en) 1994-12-08 1998-05-12 Pioneer Hi-Bred International, Inc. Reversible nuclear genetic system for male sterility in transgenic plants
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
US5880110A (en) * 1995-02-21 1999-03-09 Toyobo Co., Ltd. Production of cotton fibers with improved fiber characteristics by treatment with brassinosteroids
FR2733762B1 (fr) 1995-05-02 1997-08-01 Genset Sa Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
US5731181A (en) 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
US5760012A (en) 1996-05-01 1998-06-02 Thomas Jefferson University Methods and compounds for curing diseases caused by mutations
DE19620425A1 (de) 1996-05-21 1997-11-27 Nvg Netcard Vermarktungs Gmbh Datenträgerkarte und Vorrichtung zum Lesen/Beschreiben der Datenträgerkarte in einem Diskettenlaufwerk
US5986174A (en) 1996-06-21 1999-11-16 Pioneer Hi-Bred International, Inc. Maize promoter sequence for leaf- and stalk-preferred gene expression
US5981840A (en) 1997-01-24 1999-11-09 Pioneer Hi-Bred International, Inc. Methods for agrobacterium-mediated transformation
US6369298B1 (en) 1997-04-30 2002-04-09 Pioneer Hi-Bred International, Inc. Agrobacterium mediated transformation of sorghum
WO1998049350A1 (fr) 1997-04-30 1998-11-05 Regents Of The University Of Minnesota Utilisation in vivo d'oligonucleobases recombinagenes pour corriger les lesions genetiques des hepatocytes
WO1999007865A1 (fr) 1997-08-05 1999-02-18 Kimeragen, Inc. Utilisation d'oligonucleotides a double helice melanges pour effectuer des modifications genetiques localisees dans des plantes
AU760113C (en) 1997-11-18 2004-04-22 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
CA2315549A1 (fr) 1998-02-26 1999-09-02 Pioneer Hi-Bred International, Inc. Famille de genes pr-1 et de promoteurs
AU762993C (en) 1998-02-26 2004-06-10 Pioneer Hi-Bred International, Inc. Constitutive maize promoters
EP1033405A3 (fr) * 1999-02-25 2001-08-01 Ceres Incorporated Fragments d'ADN avec des séquences déterminées et polypeptides encodées par lesdits fragments
NL1033850C2 (nl) 2007-05-15 2008-11-18 3Force B V Brandersysteem met voorgemengde branders en vlam-overdrachtsmiddelen.
WO2015170355A1 (fr) 2014-05-05 2015-11-12 Filippo Bastianini Appareil d'interrogation de capteurs répartis à fibre optique faisant appel à un interféromètre dans le domaine fréquentiel optique à diffusion brillouin stimulée
CN105578337A (zh) 2014-10-07 2016-05-11 鸿富锦精密工业（深圳）有限公司 共振音响

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0222821A3 *

Also Published As

Publication number Publication date
US7803989B1 (en) 2010-09-28
MXPA03002218A (es) 2004-03-18
AU2001290784B2 (en) 2006-02-16
AU9078401A (en) 2002-03-26
US7807876B1 (en) 2010-10-05
EP1379658B1 (fr) 2009-01-28
EP2039769A3 (fr) 2009-06-17
EP2039769A2 (fr) 2009-03-25
US6875907B2 (en) 2005-04-05
US7393999B1 (en) 2008-07-01
ATE421992T1 (de) 2009-02-15
US7166769B1 (en) 2007-01-23
BR0113864A (pt) 2004-06-29
CA2422041A1 (fr) 2002-03-21
WO2002022821A2 (fr) 2002-03-21
US20020166141A1 (en) 2002-11-07
WO2002022821A3 (fr) 2003-10-30
DE60137587D1 (de) 2009-03-19

Similar Documents

Publication Publication Date Title
US7807876B1 (en) Antimicrobial peptides and methods of use
AU2001290784A1 (en) Antimicrobial peptides and methods of use
US6403768B1 (en) Manipulation of Mlo genes to enhance disease resistance in plants
US7767424B2 (en) Cloning and characterization of the broad-spectrum resistance gene PI2
US7041874B2 (en) Isolated nucleic acid molecules encoding the Br2 P-glycoprotein of maize and methods of modifying growth in plants transformed therewith
WO2001012801A2 (fr) Genes de signalisation lies a la defense et leurs procedes d'utilisation
US20020144307A1 (en) Plant defense-inducible genes and their use
AU772568C (en) Maize replication protein A
WO2002070723A2 (fr) Genes peroxydase de mais et leur utilisation pour ameliorer la resistance des plantes aux maladies et la solidite du pedoncule
WO2000004155A9 (fr) Compositions et procedes servant a augmenter la resistance de plantes a des maladies
AU1479401A (en) Sorghum dwarfing genes and methods of use
US20040049804A1 (en) Maize defense-inducible genes and their use
US6608240B1 (en) Sunflower disease resistance genes
US20010049834A1 (en) Maize pathogenesis-related polynucleotide and methods of use
AU1486901A (en) Sunflower rhogap, lox, adh, and scip-1 polynucleotides and methods of use
WO2001018061A2 (fr) Polynucleotides et polypeptides associes extraits du mais utilises pour renforcer la resistance aux maladies des plantes cultivees
WO2000028012A9 (fr) UTILISATION DE β-GLUCOSIDASE POUR AMELIORER LA RESISTANCE AUX MALADIES ET LA RESISTANCE AUX INSECTES DE PLANTES CULTIVEES
US6784341B2 (en) Defense-related signaling genes and methods of use
US20020166146A1 (en) Maize PR1 polynucleotides and methods of use
US20010005746A1 (en) Stomatin-like genes and their use in plants
US6660907B2 (en) Genes encoding SCIP-1 orthologs and methods of use
WO2000015818A2 (fr) Genes de prohibitine de plante et utilisation de ces derniers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030328

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/29 A

Ipc: 7A 01H 5/10 B

Ipc: 7C 12N 15/82 B

Ipc: 7G 01N 33/68 B

Ipc: 7C 12N 5/10 B

Ipc: 7A 01H 5/00 B

Ipc: 7C 12Q 1/68 B

Ipc: 7C 07K 14/415 B

17Q First examination report despatched

Effective date: 20050202

17Q First examination report despatched

Effective date: 20050202

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60137587

Country of ref document: DE

Date of ref document: 20090319

Kind code of ref document: P

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090128

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090128

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090128

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090428

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090128

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20091029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090930

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090128

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20160921

Year of fee payment: 16

Ref country code: DE

Payment date: 20160907

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20160816

Year of fee payment: 16

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60137587

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171002

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170913